Next Article in Journal
Functional Significance of Conserved Cysteines in the Extracellular Loops of the ATP Binding Cassette Transporter Pdr11p
Next Article in Special Issue
Strategies to Better Target Fungal Squalene Monooxygenase
Previous Article in Journal
Safety and Efficacy of Intermittent High-Dose Liposomal Amphotericin B Antifungal Prophylaxis in Haemato-Oncology: An Eight-Year Single-Centre Experience and Review of the Literature
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JoF
Volume 7
Issue 1
10.3390/jof7010001
jof-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Sterol 14α-Demethylase Ligand-Binding Pocket-Mediated Acquired and Intrinsic Azole Resistance in Fungal Pathogens

by
Katharina Rosam
1,
Brian C. Monk
2 and
Michaela Lackner
1,*
1
Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Schöpfstrasse 41, 6020 Innsbruck, Austria
2
Sir John Walsh Research Institute and Department of Oral Biology, Faculty of Dentistry, University of Otago, PO Box 56, 9054 Dunedin, New Zealand
*
Author to whom correspondence should be addressed.
J. Fungi 2021, 7(1), 1; https://doi.org/10.3390/jof7010001
Submission received: 2 December 2020 / Revised: 17 December 2020 / Accepted: 18 December 2020 / Published: 22 December 2020
(This article belongs to the Special Issue The Application of Structural Biology in Antifungal Drug Discovery)
Browse Figures
Review Reports Versions Notes

Abstract

:
The fungal cytochrome P450 enzyme sterol 14α-demethylase (SDM) is a key enzyme in the ergosterol biosynthesis pathway. The binding of azoles to the active site of SDM results in a depletion of ergosterol, the accumulation of toxic intermediates and growth inhibition. The prevalence of azole-resistant strains and fungi is increasing in both agriculture and medicine. This can lead to major yield loss during food production and therapeutic failure in medical settings. Diverse mechanisms are responsible for azole resistance. They include amino acid (AA) substitutions in SDM and overexpression of SDM and/or efflux pumps. This review considers AA affecting the ligand-binding pocket of SDMs with a primary focus on substitutions that affect interactions between the active site and the substrate and inhibitory ligands. Some of these interactions are particularly important for the binding of short-tailed azoles (e.g., voriconazole). We highlight the occurrence throughout the fungal kingdom of some key AA substitutions. Elucidation of the role of these AAs and their substitutions may assist drug design in overcoming some common forms of innate and acquired azole resistance.

1. Introduction

The azole drug segment has dominated the global antifungal drug market since the first-generation azoles clotrimazole and miconazole were introduced into the clinic in 1960 [1]. Currently the imidazole and triazole antifungals are the two main classes of azoles used in medicine (Figure S1). The first-generation azoles were imidazoles, while the second and third generation were triazoles [2]. The triazoles antifungals all contain a five-membered di-unsaturated ring system that includes three nitrogen atoms in a heterocyclic core [3] (see Supplementary Figure S1). The first triazole agents were marketed for agricultural use in 1973, with 31 different agents licensed since. Triazole antifungals were first licensed for use in humans in the 1990s. Today, five triazole drugs are available for therapy of systemic fungal infections: fluconazole (FLC), itraconazole (ITC), voriconazole (VCZ), posaconazole (PCZ), and isavuconazole (IVU) [4,5]. The azoles are used extensively because they are significantly less expensive than other antifungal treatments and their overall antimycotic activity is relatively broad spectrum [6]. Azole drugs are used in: (1) treatment and prophylaxis of livestock (e.g., ringworm in cattle, aspergillosis in poultry, oomycete infections in aquaculture [7,8,9,10], (2) treatment in veterinary medicine (e.g., pets and zoo animals) [11,12], (3) crop protection (e.g., mildews and rusts of grains, fruits, vegetables), (4) plant protection (e.g., leaf spot on flowers, scrubs and trees, including the timber industry) [4], (5) protection of buildings (e.g., antifouling coatings) [13], (f) cosmetic and hygiene products [14], and (6) prophylaxis and treatment in medicine [15].
With fungal pathogens estimated to cause yield losses of up to 30%, the use of fungicides is essential for efficient food production and overall food security [5]. Because azole drugs are amongst the best-tolerated and most active antifungals, they are often the first line treatment in human and veterinary medicine for many fungal diseases [4,16]. Their popularity and extensive use comes at a cost due to the resultant positive selection pressure for azole-resistance amongst fungal pathogens of plants, animals, and humans [17]. An increased incidence of intrinsically azole-resistant fungi and the emergence azole-resistant strains from naturally susceptible fungi has resulted in major losses in food production and in therapeutic failures in both veterinary and human medicine [5]. Many pathogenic molds of humans are saprophytes that decay organic matter and are ubiquitous in the environment, including agricultural soils. Application of the same drug class in medicine and agriculture, together with structural similarities among azole agents, has enabled pathogenic fungi affecting humans to have acquired azole resistance in the environment [4,18]. Moreover, mucormycetes, Fusarium spp. and Aspergillus spp. are cross-kingdom pathogens that cause infections in plants, animals and humans [19].
The target of antifungal agrochemicals (sterol demethylase inhibitors, SDIs) and antifungal drugs is the cytochrome p450 enzyme sterol 14α-demethylase CYP51 (synonym in molds; e.g., Aspergillus), ERG11 (synonym in yeasts; e.g., Candida spp.), or SDM (sterol 14α-demethylase; general term), a key enzyme in the fungal-specific ergosterol biosynthesis pathway. It catalyzes the three-step conversation of lanosterol or eburicol to a 14α-demethylated product [20,21,22]. Azole antifungals compete with the substrate by binding to the heme iron in the active site as well as other features in a ligand-binding pocket. The effective binding of azole inhibitors by SDM leads to a depletion of ergosterol, which reduces membrane fluidity, and the integrity in the lipid layer is reduced. Toxic intermediates and sterol precursors such as 14-methyl-3,6-diols accumulate. The consequence is an inhibition of the fungal growth. Azole antifungals tend to be fungistatic rather than fungicidal. This property provides fungi opportunity to adapt to this antifungal class [22,23]. Long-term use, repeated use, overuse and/or under dosing of azole drugs favor the development of azole resistance [24,25,26].
Different mechanisms at the genetic and transcriptional levels allow fungi to become resistant to azole antifungals. The most common of these resistance mechanisms are: (1) amino acid (AA) substitutions in the SDM, affecting the active site of the enzyme, (2) overexpression of the SDM, and (3) overexpression of efflux pumps such as ATP-binding cassette (ABC) transporters and/or major facilitator superfamily (MFS) transporters [22,25,27].
This review will focus on key AA substitutions associated with the ligand-binding pocket of SDMs. We will summarize the known impact of these residues on resistance to short- and long-tailed azoles in pathogenic fungi of humans, animals, and plants.

2. Azole Resistance in Fungal Pathogens

2.1. Structure of the SDM Ligand-Binding Pocket

Fungal SDM is member of the CY51 family of the cytochrome P450 superfamily found in all eukaryotes. SDM is a bitopic endoplasmic reticulum protein, which spans the lipid bilayer once [20,21,28]. In fungi, it is a key enzyme in the synthesis of the fungal specific sterol ergosterol. In plants, the enzyme is involved in the synthesis of phytosterols (sitosterol, campesterol, and stigmasterol), while in humans and animals the corresponding sterol product is cholesterol [29].
In the yeast ergosterol biosynthetic pathway, the SDM lanosterol 14α-demethylase catalyzes three reduction steps. The 14α-methyl group of the substrate lanosterol is converted first into an alcohol, an aldehyde and then released as formaldehyde together with the insertion of a 14–15 double bond yielding the reaction product 4,4 dimethylcholesta-8(9), 14, 24-trien-3beta-ol for further processing [23]. The enzyme contains an N-terminal membrane associated helix (MH1) and a transmembrane helix (TMH1), which are at an angle of 60° to each other. Hydrogen bond interactions of MH1 with the catalytic domain, which consists of about 450 amino acids, ensure that the catalytic domain is partly embedded in the lipid layer and able to access its substrate (Figure 1) [23,30]. The catalytic domain harbors an iron-containing porphyrin ring, in which the heme receives electrons from a cognate NADPH-cytochrome P450 reductase. The buried catalytic site of the protein is part of a ligand-binding pocket that includes the substrate entry channel (SEC) and a putative product exit channel [23]. Figure 1, Table 1, and Supplementary Table S1 indicate several AAs important for the binding of the SDM substrate lanosterol and inhibitory agents, respectively
Some AAs involved in azole binding in the ligand-binding pocket and/or involved in azole resistance include G73, Y140, K151, T322, and G464 (AA position according to Saccharomyces cerevisiae SDM) (Figure 1). These AAs, together with a range of additional hydrophobic interactions, stabilize ligands in the active center and complement interaction with the heme iron.
Glycine 73 (G73) in Saccharomyces cerevisiae is a non-polar amino acid in helix A’ at the mouth of the substrate entry channel. It interacts with distinct parts of long-tailed substrates such as itraconazole (ITC) and posaconazole (PCZ) and results in resistance to these long-tailed antifungals [57,58].
Tyrosine 140 (Y140) in the B-C loop of S. cerevisiae SDM structurally aligns with Y132 in Candida species (e.g., C. albicans, C. glabrata, C. parapsilosis, C. auris), Y136 in Ajellomyces capsulatus (=Histoplasma capsulatum) and Uncinula necator, Y145 in Cryptococcus neoformans, Y121 in Aspergillus species (e.g., A. fumigatus), and F129 in Rhizopus arrhizus, Mucor circinelloides, and Rhizopus microsporus (Table 1) [49,59,60]. The hydroxyl group confers polarity on the tyrosine. The substitution most commonly found is a change to a non-polar phenylalanine (F), with the loss of a hydroxyl group affecting the binding of some azole ligands and obliging a hydrogen bond with the heme ring C propionate [59].
Lysine 151 (K151) in helix C of S. cerevisiae SDM structurally aligns with K143 in Candida species (e.g., C. auris, C. tropicalis) (Table 2). The positively charged site chain forms an ionic interaction with the carboxylate group of the heme ring C propionate and loses this interaction by becoming surface exposed when lanosterol is bound. Substitution with an arginine (K151R) disrupts the ionic bond due to the larger guanidinium group [30].
Threonine 322 (T322) in helix I of S. cerevisiae SDM structurally aligns with T315 in Candida albicans and in other fluconazole-susceptible fungi (Table 2). The A. fumigatus CYP51A isoform carries a naturally occurring substitution at the structurally aligned position I301. The I301 appears to cause fluconazole resistance in A. fumigatus. This was confirmed using an A. fumigatus CYP51A knock out mutant and in a CYP51A mutant in which the non-polar I was replaced with the polar threonine (T) residue. Both A. fumigatus mutant strains showed lower resistance (20 µg/mL) compared to Aspergillus fumigatus strains carrying the naturally occurring I301 polymorphism (640 µg/mL) [36].
In the fungus-specific loop of S. cerevisiae SDM, the nonpolar G464 structurally aligns with G448 in A. lentulus, G464 in Sc. apiospermum, and G464 Candida albicans. It is most often substituted with serine (S). The S side chain contains a polar hydroxyl group that may cause azole resistance by modifying the heme environment.
In the following sections, AA substitutions in the above amino acids are discussed in the light of their impact on azole susceptibility. An overview will be provided for various pathogenic fungi of plants and animals (Table 1). AA positions were reported according to their position in the S. cerevisiae SDM.

2.2. G73 in S. cerevisiae SDM

Some AA substitutions have been reported at glycine 73 (G73). The structurally aligned mutations G54E/R/W in A. fumigatus CYP51A confer resistance to ITC and PCZ, but retain susceptibility to VCZ. This is thought to be due to long-tailed azole-specific interactions with the mouth of the SEC [61,62]. Sagatova et al. generated S. cerevisiae mutant strains carrying the following SDM mutations: G73E, G73R, and G73W, respectively [58]. The SDM G73E/R enzymes supported yeast growth, but SDM G73W did not, suggesting a significant impediment in the SEC. The SDM73E/R strains showed 2.5-fold increases in susceptibility to FLC, VCZ, and ITC and type II binding studies showed these drugs and PCZ bound tightly to the affinity purified wild-type and mutant enzymes. Crystal structures obtained for the SDM Y73E and SDM 73W enzymes showed that ITC adopted bent conformations different to that found with the wild-type enzyme [58]. Despite visualization of inhibitor conformation, the inability of the mutated yeast SDM to mimic the expected resistance pattern reported by Alcazar-Fuoli et al. for A. fumigatus CYP51A expressed in S. cerevisiae is an important limitation that emphasizes the need to obtain a full-length structure of A. fumigatus CYP51A [63].

2.3. Y140 in S. cerevisiae SDM

Mutations or substitutions structurally aligned with SDM Y140F are prevalent in many species, e.g., A. fumigatus CYP51A Y121F, Candida species SDM Y132F, Cryptococcus neoformans SDM Y145F, Scedosporium apiospermum SDM Y136F, Ajellomyces capsulatus SDM Y136F, and mucormycete SDM Y129F. The same modification is frequently found in fungal phytopathogens, e.g., Blumeria graminis SDM Y136F and Parastagonospora nodorum SDM Y144F (Table 1).
The Y140F substitution is important as the Y hydroxyl group not only forms a hydrogen bond with the heme ring C propionate but can also form a water-mediated hydrogen bond with the tertiary alcohol of short-tailed azoles such as FLC and VCZ (Figure 1). The Y140F mutation therefore leads to a lower affinity for such drugs and may also reduce the stability of the enzyme [59]. Some known resistance phenotypes are summarized in Table 1. Fungal pathogens of plants and animals harboring this AA substitution are resistant to commonly used short-tailed azoles. Positive selection pressure in azole-rich environments leads to increased prevalence of isolates with SDM mutations equivalent to Y140F [64,65,66]. Some intrinsically resistant species (e.g., mucormycetes) also carry the comparable substitution [49]. In agriculture, SDIs such as tebuconazole (TBC), epoxiconazole (EPC), and triadimenol (TDM) are used. The structures of some SDI and azole drugs used most commonly in agriculture and medicine are given for comparison in Supplementary Figure S1. There are significant structural and functional similarities between FLC and VCZ and the SDIs used in agriculture. The agrochemicals are of comparable size to FLC and VCZ and occupy the active site, but not the SEC. Like FLC and VCZ, the agrochemicals TDM, TBC, and prothioconazole-desthio all contain a hydroxyl group capable of water-mediated hydrogen bond contact with residues equivalent to S. cerevisiae SDM Y140. Recombinant S. cerevisiae SDM Y140F/H mutants confer significant resistance to R-TBC and S-prothioconazole-desthio [67]. These two compounds show tight type II binding to S. cerevisiae SDM and in crystal structures are in positions that would allow for the formation of a water-mediated hydrogen bond network with Y140. In contrast, no significant resistance was conferred to prochloraz, which cannot form such as network and is more weakly bound in the active site of S. cerevisiae SDM despite being an imidazole rather than a triazole. Surprisingly, the S. cerevisiae SDM Y140F/H mutations conferred significant azole resistance to the triazole agrochemical difenconazole which contains a 4-methyl-1,3 dioxylane ring that was shown to be in crystal structures to displace the water contributing to Y140-associated hydrogen bond network [67]. Its resistance might instead be due to effects on the Y140F/H mutations on the alignment of the dichlorophenoxyphenyl head group of difenoconazole with the F384 in helix I.
The binding of long-tailed azoles within the active site also involves the heme iron and hydrophobic interactions in common with the short-tailed azoles, but the binding of ITC and PCZ is unaffected by the Y140F/H substitution as these drugs do not contain the relevant tertiary alcohol group. The long-tailed azoles also have additional interactions within the SEC that are not available to the short-tailed azoles bound within the active site. For example, the N1 in the piperazine ring of itraconazole and posaconazole interacts with a water-mediated hydrogen bond network involving the main chain amino groups of H381 and S382 in S. cerevisiae SDM (Figure 1). This water-bearing pocket is probably important for locating the hydroxyl group so that lanosterol binds in a catalytically competent position in the active site (Figure 2).

2.3.1. Aspergillus Species

The genus Aspergillus includes several pathogenic species of which A. fumigatus is the most abundant [25]. Aspergilli can cause allergies and both acute and chronic infections [65]. The most recent ESCMID (European Society of Clinical Microbiology and Infectious Diseases) -ECMM (European Confederation of Medical Mycology)-ERS (European Respiratory Society) guideline recommends VCZ as first line treatment of invasive aspergillosis, with liposomal amphotericin B (AmB) or isavuconazole (IVU) as alternative therapies [68]. VCZ is the treatment of first choice for aspergillosis due to its broad-spectrum activity that also covers infections with less common aspergilli such as A. terreus, its cost advantage compared with liposomal amphotericin B, the availability of oral and intravenous formulations, and its better tolerability than AmB [69,70].
Aspergillosis not only affects humans but also poultry [71], captive wild birds (e.g., water birds and penguins in zoos) [72] and wild birds [73]. Recently, an outbreak of aspergillosis was reported in the endangered kakapo population of New Zealand [74]. The same range of antifungals used in human medicine is used to treat avian aspergillosis [73]. Aspergilli are saprophytic fungi ubiquitous in the environment (including soil and compost). They are dispersed widely by air and are among the most commonly detected airborne fungi [75]. Some industries, such as tulip production, apply large quantities of azole agrochemicals. The abundance of azole-resistant A. fumigatus strains has been correlated with close proximity to azole-rich environments [76,77,78].
The rise of VCZ-resistant isolates of A. fumigatus has reduced the efficacy of VCZ prophylaxis and treatment. While the A. fumigatus CYP51A TR34 L98H mutant was initially reported, CYP51A TR46/Y121F/T289A is among the most prevalent mutations found in clinical and environmental isolates of this pathogen [79,80]. Y121F in A. fumigatus CYP51A predominantly occurs together with the T289A mutation in helix I plus the TR46 (46 base pair tandem repeat) in the CYP51 promoter. Although, T289A occurs in natural isolates, but does not itself confer azole resistance [31]. Snelders et al. used laboratory strains to show that TR46 results in overexpression of the CYP51A gene and increased production of SDM [31]. They also found that while the TR46/Y121F mutant showed high voriconazole and itraconazole resistance (>8.0 mg/L), the TR46/Y121F/T289A mutant was susceptible to itraconazole (0.5 µg/mL) but not to voriconazole (>8 µg/mL). It was suggested that T289A mutation moderates resistance to itraconazole but is needed to counterbalance the harmful effect of Y121F on normal protein function. This view is supported by the fact that the three mutations are most frequently found together in environmental isolates [31]. The abundance of strains with the resistance genotype TR46/Y121F/T289A is increasing, especially in environments with positive selection pressure for azole resistance (e.g., in vineyards and tulip compost) [77,81].
VCZ resistance is not restricted to A. fumigatus sensu stricto and occurs in other species of the section Fumigati. The Fumigati contains closely related species that are morphologically indistinguishable from A. fumigatus [82]. Among sibling species pathogenic in humans are A. lentulus and A. felis [83]. Reduced azole susceptibility is a species-specific feature of A. lentulus, although the exact mechanism has yet to be elucidated. Minimal inhibitory concentration (MIC) levels are generally high for ITC (0.43–16 μg/mL), VCZ (3–7.5 μg/mL), and PCZ (0.12–2.0 μg/mL) [84,85]. Experimentally, this reduced susceptibility to azole drugs (5- to 100-fold) can be attributed to the CYP51A gene. Deletion mutants of CYP51A (Δcyp51A) had lower MICs to ITC (0.03–0.06 μg/mL), VCZ (0.25 μg/mL), and PCZ (0.015 μg/mL). A. fumigatus and S. cerevisiae mutants, carrying the A. lentulus CYP51A gene, showed higher MICs to ITC (0.5–8.0 μg/mL), VCZ (1.0–4.0 μg/mL), and PCZ (0.12–0.25 μg/mL) [86]. Alcazar-Fuoli et al. used a three-dimensional model of A. lentulus CYP51A to suggest that the lower susceptibility to VCZ of A. lentulus is due to decreased affinity between the azole and the SDM [37]. The rare, but potentially underdiagnosed species A. felis has also a reduced susceptibility to VCZ and ITC, but the mechanism responsible has not been determined. The possibility of a Y121F mutation was suspected, but this idea requires further research [86].

2.3.2. Candida Species

Candida species are the most frequently diagnosed fungal pathogens in humans. They can cause a variety of diseases, ranging from superficial mucosal infections to deep-seated infections such as candidemia [16]. The most prevalent species is C. albicans, followed by C. glabrata, C. tropicalis, C. krusei, and C. parapsilosis [16,87]. A species of increasing concern is C. auris. This species has recently evolved as a significant human pathogen. It was first isolated in 2007 as an azole-susceptible strain from an aural sample of a female Japanese patient [60]. The first hospital outbreak was reported in Europe in 2016 and was due to a multidrug-resistant strain of the species C. auris [88]. Since then, C. auris strains have spread globally and they are now recognized by the CDC to be a serious global health threat [89].
Globally, the antifungal agent most commonly used for the treatment of Candida infections is fluconazole, followed by the echinocandins [90]. Fluconazole resistance in Candida species is a major concern. The majority of the Candida species, including C. albicans, are naturally fully susceptible to fluconazole. This contrasts with molds, which are all intrinsically resistant to fluconazole. Resistance against FLC and VCZ in Candida species has frequently been linked to the SDM Y132F/H mutations. These SDM mutations have been reported for species including C. albicans, C. tropicalis, and C. parapsilosis and they lead to both FLC and VCZ resistance. (Table 1). The SDM Y132F substitution has been most extensively studied in C. albicans. It significantly (16-fold) increases VCZ and FLC MICs in this yeast while the Y132H gives an 8-fold increase [45].
Candida parapsilosis has emerged as the most prevalent Candida species detected in South Africa (58–63%). In other regions, including Latin America, the United States of America, Asia, and Western Pacific, the prevalence of C. parapsilosis is much lower (1%–7.7%). A 2009–2010 study showed that approximately 80% of all C. parapsilosis strains are FLC resistant. The SDM Y132F mutant was found in 68% of all FLC-resistant strains [27]. The incidence of FLC resistance in C. parapsilosis is alarming as FLC is the antifungal drug used most often in developing countries [91]. C. parapsilosis is a commensal of the skin and, unlike other fungi, is easily transmitted by healthcare workers, resulting in major hospital outbreaks. Isolates causing such outbreaks tend to be more virulent than isolates causing sporadic cases [92]. In Turkey, a single center study tracked the prevalence of C. parapsilosis with the evolution of azole resistance over time. The FLC resistance can either be acquired due to the positive selective pressure in azole-rich environments or due to horizontal transfer from other individuals. Arastehfar et al. found that SDM Y132F and the SDM Y132F K143R combination occurred in clinical outbreak strains [91]. The outbreak strains were of clonal origin and this correlated with the abundance of strains harboring SDM Y132F. Mortality rates of patients infected with FLC-resistant C. parapsilosis strains were higher than for patients infected with FLC-susceptible strains [91].
A major concern is the multidrug resistance of Candida auris isolates. In the last five years, four phylogenetically clades of C. auris have been described that correlate with different geographical origins: the South Asian clade, South American clade, African clade, and the East Asian clade [93]. Each clade has specific resistance profiles and carries different adaptive mutations [94]. The SDM F126T mutation is strongly associated with the African clade while SDM Y132F is most prevalent in the South American clade. Strains of the South Asian clade carry most frequently the Y132F and/or K143R substitutions, especially clinical isolates from India and Pakistan [94,95]. As the type strain (East Asian clade) isolated in 2007 is fully susceptible to all systemically applied antifungal agents, Candida auris has revealed how antifungal resistance can evolve quickly in an emerging fungal pathogen. In less than two decades, and depending on the clade, up to 100% of Candida auris strains have become FLC resistant and 41.1% VCZ resistant [60,96,97]. The two most common mutations found in C. auris SDM are Y132F and K143R. The latter mutation will be discussed in Section 2.3.4. The haploid nature of C. auris allows for such a rapid resistance development.

2.3.3. Cryptococcus Species

The genus Cryptococcus includes several human pathogens. The most common of these are Cr. neoformans and Cr. gattii. Cryptococcus neoformans causes meningoencephalitis, mostly in immunocompromised patients, such as AIDS patients [44,98]. Cryptococcosis contributes significantly to the high mortality rates of HIV-infected patients worldwide. In addition, some immunocompetent patients can suffer from cryptococcosis [44,98]. Cryptococcus grows as yeast in the host and the environment. In the human host, the fungus grows as a capsulated yeast. Similar to Candida, Cryptococcus is naturally fully susceptible to fluconazole. Fluconazole as a single drug therapy or combination with 5-fluorocytosine (5-FC) is a first line treatment for cryptococcosis [99]. Fluconazole is often the treatment of choice as the drug is inexpensive, widely available in emerging economies and can be used for long-term therapy due to its low toxicity and good penetration of the central nervous system [44].
Cryptococci are basidiomycetes that cause major disease outbreaks around the globe. As these outbreaks are clonal, the increased incidence of fluconazole resistance in Cryptococcus populations is a major concern [100,101,102]. Cryptococcus neoformans and Cr. gattii have innate heteroresistance to azoles, an adaptive mechanism involving duplication of chromosomes containing specific genes that confer azole tolerance [103].
The Cyptococcus SDM Y145F mutation (SDM Y140F in S. cerevisiae) is one of the mutations that confers resistance to FLC and VCZ. A biochemical test of this relationship is needed for Cr. neoformans and Cr. gattii [44]. In Taiwan, the frequency of resistance to FLC among Cr. neoformans strains has increased from 0–33% in 2001–2006 to 75–88% in 2011–2012 [104]. In order to track and control resistant Cryptococcus strains, MIC determinations should be standard practice [105].

2.3.4. Saccharomyces cerevisiae

S. cerevisiae infections in humans are very rare. However, blood stream infections due to S. cerevisiae have been reported in COVID-19 patients [106] In the West, the yeast Saccharomyces cerevisiae is the fungus used most in food industries, e.g., fermented foods including wine, bread, chocolate, and beer [106]. S. cerevisiae is also used to produce biofuel [107], dietary supplements [108,109], and it provides cell factories that produce human insulin and other medications [110].
In the life sciences, S. cerevisiae is one of the most widely used eukaryotic model organisms because it is easy to culture, genetically manipulate and study biochemically [111]. S. cerevisiae has been used as a model to elucidate the impact of SDM ligand-binding site mutations in various pathogenic fungi [59]. In order to assess azole susceptibilities of heterologous expressed SDMs, a host strain deleted of drug efflux pumps can be used to minimize their effect. In addition, if the heterologous expressed SDM is functional, the native SDM can be deleted [59]. The first crystal structures of full-length heterologous expressed recombinant fungal SDM in S. cerevisiae were from S. cerevisiae itself and then from C. albicans and C. glabrata. The high-resolution structures of wild-type and mutant SDMs in complex with substrates and inhibitors provide insight into associated phenotypes and biochemical changes and can now underpin structure-directed antifungal research and discovery [20]. Thus far, S. cerevisiae SDM has provided an effective surrogate to study mutations in the SDM of Candida species [21,58].

2.3.5. Scedosporium species

Azole resistance in Scedosporium apiospermum is not well understood. To our knowledge, a single study has analyzed azole resistance patterns and correlated them with AA substitutions in the Sc. apiospermum SDM [50]. Similar to other molds, Scedosporium species have two SDM-encoding homologs, namely, CYP51A and CYP51B. VCZ is the first line therapy for scedosporiosis [112]. The susceptibility of Scedosporium to azole drugs seems to be species specific. Sc. aurantiacum strains are often resistant to PCZ while the majority of strains in the Sc. apiospermum species complex are susceptible to PCZ, and with PCZ resistance more common than VCZ resistance [113]. Bernhardt et al. described VCZ-resistant Sc. apiospermum strains harboring the SDM Y136F substitution in their CYP51A gene [50]. While this mutation in the SDM active site may be prevalent in Scedosporium species, further research is needed to elucidate its impact on resistance to short-tailed azoles.

2.3.6. Ajellomyces capsulatum

The dimorphic ascomycete Ajellomyces capsulatum, better known in medical settings as Histoplasma capsulatum, is the causative agent of histoplasmosis, the most frequent endemic mycosis in the United States of America [114]. The dimorphic fungus grows as a filamentous fungus in the environment and as a yeast in the human host. It is a progressive clinical illness that can spread from the lung, especially in immunocompromised patients [115]. ITC is the azole used most frequently to treat histoplasmosis although FLC is an option when ITC cannot be applied for other reasons [114]. One third of histoplamosis patients treated with FLC experience a relapse. Isolates from relapse patients were found to have higher FLC MICs [114]. Their FLC resistance was linked to SDM Y136F and these isolates had a 4-fold higher VCZ MIC [114].

2.3.7. Innate Azole Resistance of Mucormycetes

The incidence of mucormycete infections appears to be increasing globally. Their incidence is under-reported as the disease is often misidentified because it is often hard to differentiate from other mold infections. Several mucormycetes cause severe infections in immunocompromised patients. The prevalence of individual species varies between countries. In Europe and Africa, the species reported most frequently as causing mucormycosis was Rhizopus arrhizus followed by Lichtheimia corymbifera [116]. Patients suffering from invasive mucormycosis have mortality rates that approach 96%. The current first line treatment is liposomal amphotericin B, with posaconazole used as a salvage therapy. Mucormycetes are intrinsically resistant to short-tailed azoles. VCZ, used widely as prophylaxis against aspergillosis in high-risk patients is not effective for mucormycosis. This intrinsic resistance involves two natural occurring SDM substitutions, F129 and V291 [49]. While other fungi can acquire comparable resistance-conferring mutations, the substitutions in mucormycetes seem to be evolutionary conserved. Thus far, they have been found in all mucormycete whole genome sequences.

2.3.8. Agricultural Pathogens

The triazoles are amongst the most widely used fungicides in agriculture. The first SDM Y136F mutation found in a fungal phytopathogen was associated with reduced TDM susceptibility. SDM Y136F has now been reported in a variety of agricultural important pathogens: Blumeria graminis (Y136F), Mycosphaerella graminicola (Y137F), Parastagnospora nodorum (Y144F/H), Puccinia triticina (Y134F), and Uncinula necator (Y136F) (Table 1 and Table 2). The associated azole resistance patterns are shown in Table 1. The chemical structures of the triazoles used in agriculture and medicine are often similar (Figure S1), so the occurrence of comparable mechanisms of resistance among crop and medically important pathogens is not surprising [117]. According to the risk assessment of the European center for disease control and prevention (ECDC), the most used triazoles in agriculture are prothioconazole, TBC and EPC in the United Kingdom, Denmark, and the Netherlands. Chemically, they belong to the group of short-tailed azoles [118] (Figure S1).
Mycosphaerella graminicola (Zymoseptoria tritici) causes septoria leaf blotch in wheat, which causes crop losses of up to 50% [43]. SDIs are fungicides commonly used against the septoria leaf blotch. Exposure of Mycosphaerella graminicola to TDM from the 1980s led to the acquisition of the SDM Y137F mutation. Its replacement with EPC and prothioconazole has resulted in the emergence of a range of alternative SDM mutations [52,53].
Blumeria graminis, the most common ascomycetous fungal pathogen infecting barley crops, causes a powdery mildew that reduces barley yields by 20–40% [51,119]. In Blumeria graminis, SDM Y136F has been found together with the S509T mutation [51]. Isolates with this genotype are resistant to TBC [51].
Parastagonospora nodorum is an ascomycete and the causative agent of the global crop disease Stagnospora or Septoria nodorum leaf and glume blotch [54]. The economic impact of this fungal disease is difficult to determine, but has been estimated to cause up to 30% yield loss in Australia. Isolates of Parastagonospora nodorum with a reduced susceptibility to propiconazole or TBC were found to carry either the SDM Y144F or Y144H mutations, respectively [54].
Puccinia triticina is a basidiomycete that causes the brown rust or leaf rust. It is a common pathogen of wheat that causes up to 50% crop loss [120]. The acquired SDM Y134F mutation has been reported to contribute to reduced EPC susceptibility, but additional mechanisms may contribute to the resistant phenotype [121]. An accompanying mutation similar to A. fumigatus T289A may be involved.
Uncinula necator is an ascomycete that causes powdery mildew. It is the major fungal pathogen found in grapevines. Powdery mildew is controlled by extensive use of fungicides, including SDIs [121]. Its economic importance stimulated the first study of the mechanism underlying azole 2resistance in a crop pathogen. Modification in the SDM ligand-binding pocket has been linked with SDI resistance patterns [56]. SDM Y136F was found to be associated with TDM resistance [122], with isolates carrying this point mutation having reduced susceptibility to TDM [123].
The impact of azole-resistant fungal pathogens in agriculture is an underrated problem. Most crops needed for the food supply are affected by fungal pathogens. Harvest losses caused by phytopathogens can be expected to cause food shortages for a steadily increasing human population. With extensive use of SDIs, resistance patterns that compromise their efficacy will continue to evolve. Novel antifungal agents are needed in human medicine and to guarantee efficient food production.
Further research is needed to understand why the mutations structurally aligned with S. cerevisiae SDM Y140F/H are, or have been, prevalent in fungal pathogens of medical or agricultural importance. We hypothesize that it represents a pan-fungal kingdom mutation that is readily induced by small azole antifungals reliant on interactions within the active site of SDM.

2.4. K151 (According to S. cerevisiae SDM)

The SDM K143R substitution is an acquired mutation in Candida species, including C. auris and C. tropicalis [43,124]. It has been suggested that the SDM K143R mutation interferes with the entry of the azole or its binding with the active site [97]. The substitution is predicted to modify the ionic bond with the heme ring C propionate and affect the conformation of β-bulge [20].
The high FLC and VCZ resistance of the emergent multidrug-resistant pathogen C. auris has been associated with a K143R mutation that confers MIC ranging from 32 to 128 µg/mL for FLC and 0.25 to 2 µg/mL for VCZ [125,126].
There have been several outbreaks of C. auris in hospital settings, especially in intensive care units, e.g., at Oxford University Hospital. Transmission was shown to be due to reusable axillary temperature probes. The testing of isolates according to the Sensititre YeastOne system found that 100% of the strains were resistant to FLC, 98% to VCZ, and 90% to PCZ, according to C. albicans breakpoints [127]. Other recent outbreaks have occurred in Valencia [128] and London [88].
Heterologous expression of in Escherichia coli of C. albicans SDM carrying the K143R mutation was reported to confer fluconazole resistance in vitro [97].

2.5. T322 (According to S. cerevisiae SDM)

2.5.1. Aspergillus fumigatus

A. fumigatus has two homologous copies of the SDM-encoding genes, namely, CYP51A and CYP51B. CYP51A is considered to be the workhorse of the ergosterol pathway. A recently discovered natural CYP51A I301 polymorphism was postulated to cause the FLC resistance of A. fumigatus. In the CYP51B homologue of A. fumigatus, T304 is structurally aligned with I301 [36]. The I301 polymorphism results in the loss of a possible hydrogen bond that has been linked to a change in the flexibility of helix I [36]. CYP51A I301 together with S297 have been postulated to be essential for the modified interaction of FLC within the active site of the enzyme [36].

2.5.2. Candida albicans

Lamb et al. postulated that the acquired SDM T315A mutation Candida species leads to fluconazole resistance [41]. Using S. cerevisiae SDM mutants, they found T315A, which is equivalent to I301 in A. fumigatus CYP51A (see 2.5.1), reduces fluconazole susceptibility 4–5-fold. As this mutation is due to one single nucleotide polymorphism, it might be acquired easily in environmental and clinical settings [41].

2.6. G464 (According to S. cerevisiae SDM)

2.6.1. Glycine G464S/D

The SDM G484S mutation has been linked with FLC resistance [47]. Forastiero et al. also constructed C. tropicalis G484D mutants [129]. It was suggested that the C. tropicalis SDM G464S or G464D affects the environment of the SDM heme group due to the nucleophilic serine or acidic aspartic acid side chains [129]. C. albicans SDM G464S gave a 2- and 4-fold increase in FLC and VCZ MICs, respectively. The combination of SDM G464S and D278N further increased resistance to FLC and VCZ [130].
The use of S. cerevisiae models showed that resistance to FLC was conferred by G464H alone or in combination with other mutations. The combinations included Y132H and R467K or Y132H and H283R. The G464S Y132H combination showed a 32-fold increase in FLC resistance. As these amino acids are located at, the opposite site of the heme, crystal structures of S. cerevisiae SDM were used to show that the G464S hydroxyl replaces a water that normally creates a hydrogen bond with the heme ring D propionate [58].
Sc. apiospermum SDM G464S structurally aligns with the A. fumigatus CYP51A G448S. Mutations in G448 were reported to confer reduced susceptibility to VCZ, ITC, and PCZ, but further information on the binding of antifungal agents and its impact on azole resistance is needed [50].
The Cr. neoformans SDM G484S structurally aligns with S. cerevisiae SDM G464S. Its correlation with the development of azole resistance led to Cr. neoformans SDM G484 being suggested as a mutational hot spot [47]. The Cr. neoformans SDM G484S conferred FLC, but not to VCZ or ITC resistance [47].

2.6.2. Glycine G460 in M. graminicola

Mycosphaerella graminicola SDM G460 mutations occur frequently. The M. graminicola SDM G460D mutation was first described in 1992. Strains with SDM G460 deletions (Δ460) were also found in Germany in 2004 [131]. Mycosphaerella graminicola SDM Δ459 andΔ460 strains have been successfully engineered. These deletions and other AA substitutions in positions 459–461 are prevalent in several environmental strains with increased resistance to azoles. As G460 is part of the fungus-specific loop, early studies suggested it is involved with docking with TDM or prochloraz. The Y459 and G460 deletions were proposed to increase cavity volume and impact on resistance patterns [52]. It more likely that these mutations cause a misfolded fungus-specific loop that affects the binding efficiency of the cognate NADPH-cytochrome P450 reductase. The reductase is essential for reducing the SDM heme iron. Interactions of SDIs with the heme including direct completion with the substrate can be expected to more strongly affect the activity of short-tailed SDIs that are bound entirely within the active site. Such interactions have a lesser effect on long-tailed SDIs that have additional interactions with the SEC.

3. Discussion

Mutations or substitutions structurally aligned to S. cerevisiae SDM Y140F/H are prevalent in many fungal pathogens of plants, animals, and humans. This type of modification appears to provide a pan-fungal kingdom resistance mechanism for fungi exposed to short-tailed azole drugs or agrochemicals. The mutation is found in basidiomycetes (Cryptococcus neoformans, Puccinia triticina) ascomycetes (Ajellomyces capsulatus, Aspergillus spp., Candida spp. Kluyveromyces marxianus, Scedosporium apiospermum, Blumeria graminis, Mycosphaerella graminicola, Parastagonospora nodorum, Uncinula necator) and mucormycetes (Rhizopus arrhizus, Rhizopus microsporus, and Mucor circinelloides). Contamination of soils and sweet- and salt-water bodies with azole antifungals, due to agricultural leaching and aquaculture makes it likely that comparable substitutions are likely to occur even in phylogenetically ancient groups of fungi such as chytridiomycetes and oomycetes. In ascomycetes and basidiomycetes, mutations equivalent to Y140F/H are acquired adaptations to azole drug exposure [44,132]. The structurally aligned SDM F129 is a naturally occurring substitution that is evolutionary conserved among mucormycetes [49]. The mutation has been linked with resistance to short-tailed azoles (e.g., VCZ, FLC, TBC, PPC, TDM, and EPC) in fungal pathogens of both plants and humans (Table 1). This resistance mechanism indicates the importance that this AA position in the binding short-tailed SDIs. The hydroxyl group of the tyrosine forms a structure—a stabilizing hydrogen bond with the heme ring C propionate and a water-mediated hydrogen bond network with the tertiary hydroxyl group in short-tailed azoles including FLC, VCZ, TDM, and TBZ in the target active site. This binding is important for short-tailed azoles as they form fewer interactions in the ligand-binding pocket than long-tailed azole drugs such as ITC and PCZ, which form additional hydrophobic contacts and water-mediated hydrogen bonds in the SEC. Although both short- and long-tailed azoles bind to the heme iron and have multiple hydrophobic interactions within the active site, for short-tailed azoles, the water-mediated hydrogen bonding in the active site contributes to an overall binding affinity that allows for effective competition with substrates such as lanosterol and eburicol.
In mucormycetes and aspergilli, an accompanying structurally aligned innate substitution (A291 in mucormycetes) or acquired mutation (T289A in Aspergillus) was postulated to confer resistance to the short-tailed azole VCZ (Table 1). For mucormycetes, it remains to be proven, experimentally, that the combination of these F129 and A291 substitutions is essential for resistance to both VCZ and FLC. In addition, in Aspergillus insertion in the CYP51A promoter of the 46 bp, TR46 tandem repeat was also required to confer the resistance [31]. While SDM Y121F alone increased the VCZ MIC to 4 mg/mL and T289A alone did not affect the MIC, both mutations were required to increase the VCZ MIC to 8.0 µg/mL. When TR46 was inserted into the strains carrying either Y121F or both mutations (Y121F and T289A), the MIC for VCZ was >8.0 µg/mL. Isolates carrying either or both active site mutations, but lacking the TR46 promoter modification, remained fully susceptible to ITC and PCZ. These results confirmed that the combination of the two active site mutations plus enzyme overexpression conferred resistance to short-tailed azoles.
Other ligand-binding pocket associated substitutions detected less frequently are known to be involved in acquired or intrinsic resistance but have not been found in such a diverse range of fungal pathogens. SDM K143R/Q mutations have been described as single substitutions or occurring with Y132F. Thus far, this mutation has only been described in Candida species [43,122,124]. In particular, non-albicans species (C. auris, C. tropicalis, C. orthopsilosis) and strains causing clinical outbreaks have been found to carry such mutations [43,124,125]. In molds such as Aspergillus, this residue does not seem to play a role in azole resistance.
Intrinsic fluconazole resistance in A. fumigatus appears to be mediated via SDM 301I [36]. This finding was confirmed using recombinant strains. An I301T mutant exhibited a much lower FLC MIC (20 µg/mL) than the parental strain (640 µg/mL) while the MIC for other azole drugs was unchanged. SDM in FLC-susceptible fungi such as Candida albicans carries the structurally aligned polar AA T315. This residue is too distant to affect the binding of FLC directly and it sidechain hydrogen bond is instead thought to increase the flexibility of helix I. The non-polar I301 in A. fumigatus SDM cannot form this hydrogen bond and will therefore expected to stiffened helix I. Whether this AA substitution mediates FLC resistance in other intrinsically FLC-resistant molds remains to be determined.
Mutations structurally aligned with S. cerevisiae SDM G73 and G464 are infrequent. A more comprehensive picture of the relevance of all the ligand binding site substitutions and their impact on long- and short-tailed azole resistance requires further structural and functional analysis.
We are confident that AA mutations/substitutions structurally aligned with S. cerevisiae SDM Y140, K151, and V311 we have described represent the tip of an iceberg across the fungal kingdom. Fungi occur in almost all known ecological niches. Most of these niches can be contaminated with azoles, but their impact is poorly understood. While it is clear that there is positive selection pressure for azole-resistant strains and species, how the complex composition of fungal communities in different niches is affected is not known. Current reports of SDM binding site mutations are limited to a few fungal pathogens of plants and animals. The effects of azole contamination that does not directly affect commercial production or human health are not known, e.g., how is fungal biodiversity affected in azole contaminated water and soils?
Fungi with acquired azole resistance are likely to have a fitness advantage in azole-contaminated environments [18,133,134,135,136,137]. In addition, fungi such as mucormycetes that are intrinsically resistant to short-tailed azoles should benefit from a positive selection pressure in azole-rich environments and outcompete azole-susceptible species [137]. It is also problematic that agrochemicals such as TDM have very long half-lives, ranging from 110 to 375 days in soil [138]. Azole residues have been detected in foods including strawberries, apples, grapes, and peppermint, in some cases reaching peak values of up to 0.5 mg/kg to 0.8 mg/kg [139]. It has been shown that agricultural imports provide a possible route for the intercontinental spread of resistant fungi. This raises the concern that strains harboring CYP51A mutations may encroach into clinical settings [76,77]. Azole inhibitor intake could favor selection of azole-resistant Candida species or isolates with acquired azole-resistance in patients’ mycobiomes. The use of cosmetics and personal hygiene products containing azole antifungals may aid colonization of hair and skin with azole-resistant Candida species [140]. While little evidence supports a shift towards an azole-resistant mycobiome in patients due azole contaminated food and hygiene products, previous azole-treatment in patients is clearly linked with azole treatment failure [24].
High prevalence of mucormycetes in homes and workspaces (bakeries, pig farms, taxis, waste-sorting plants) has been confirmed [137]. Selection pressure contributes to changes in the mycobiome composition of such niches. This may partially explain the rise of mucormycete infections worldwide. The use of FLC/echinocandins and VCZ as a first line prophylaxis against the most prevalent fungal pathogens Candida and Aspergillus, respectively, has created azole-rich niches in patient cohorts. Because mucormycetes are intrinsically resistant to FLC, echinocandins and VCZ, high-risk patients receiving antifungal prophylaxis with any of these three agents can provide a suitable niche for these fungi. The presence of SDIs in agricultural soils and on food might contribute to significant exposure of these patient cohorts. For example, contamination of flour and bakeries with azole-resistant aspergilli and mucormycetes has recently been found and the associated risk of exposure to bakers of these azole-resistant fungi discussed [141]. Professions at risk of even higher exposures include agricultural workers, farmers, composters, gardeners, and millers. Since the majority of mold infections are airborne and azole-resistant molds may be readily dispersed by wind, susceptible individuals living close to farms with intensive azole use are at risk, as has been shown for the Netherlands and the UK [76]. Furthermore, azole-resistant aspergilli associated with tulip bulbs and potted plants can be transported from the flowerbed to the patient bed, e.g., from the Netherlands to distant countries such as Japan [76,77].
We need to limit the use of azole drugs and agrochemicals by applying them more judiciously. A key aim should be to reduce azole contamination of the environment and in food. Ideally, azoles should be used for very specific applications and a strict structural separation of azole inhibitors used in agriculture and medicine is required. The wide availability of azoles favors the emergence of azole-resistant fungi. Within a few decades, azole-resistance may become so wide spread that the utility of this valuable substance class will be lost to both agriculture and medicine. By understanding the molecular basis of azole binding to its target, it should now be possible to design azole inhibitors that meet these challenges.

4. Conclusions

New antifungal compounds are urgently needed due to the emergence of azole- and multidrug-resistant fungi. Understanding the mechanism of acquired and intrinsic azole resistance in a wide range of fungal pathogens is therefore highly relevant to the field of antifungal drug discovery.
The linkage of azole resistance in agriculture and medicine is a major problem that needs to be addressed. Two major concerns are: (1) the exposure of people to azole drugs via azole-contaminated food products and subsequently the selection pressure on the human mycobiome, and (2) the selection for and evolution of azole-resistant fungal pathogens in the environment. Azole resistance in the medical setting is particularly troublesome since only three major substances classes are available for the treatment of systemic fungal infections (polyenes, echinocandins, and azoles). Some fungal pathogens of humans have intrinsic resistance against one or multiple drug classes, narrowing treatment options. The addition of acquired azole resistance can often make combination therapies the only treatment option.
We suggest that drugs used in the clinical setting need to differ structurally from those used in agriculture, if they act via the same cellular mechanism. For example, should long-tailed azoles be reserved for medical applications and not developed as agrochemicals? The alternative is to focus on the development of separate drugs and agrochemicals that attack different cellular targets in order to overcome the cross-habitat resistance found throughout the fungal kingdom.
The knowledge gained from understanding how key AA changes in the ligand-binding pocket of SDMs affect substrate and inhibitor binding can now be used to design a new generation of azole drugs that are more potent and resistant to fungal adaptation via the known mechanisms. Stronger binding could be achieved by modulating key interactions of these ligands with the active site and the substrate entry channel of SDMs.

Supplementary Materials

The following are available online at https://www.mdpi.com/2309-608X/7/1/1/s1, Figure S1: Structures azole drugs and agrochemicals. (A) Imidazole and 1,2,4 triazole substituents. (B) Sterol 14α-demethylase inhibitors used as triazole drugs. (C) Sterol 14α-demethylase inhibitors used as fungicides as agrochemicals. Fluconazole, voriconazole, propiconazole, tebuconazole, epoxiconazole and triadimenol are short-tailed azole drugs. Isavuconazole is a mid-tailed azole drug. Itraconazole and posaconazole are long-tailed azole drugs. Structures were modified from https://www.sigmaaldrich.com, 27.10.2020; Table S1: Sterol 14α-demethylase amino acid substitutions and their phenotypic effects; Table S2: EUCAST Clinical Breakpoints (CBPs) of human pathogenic fungi; Table S3: Itraconazole and lanosterol binding plus innate resistance in eukaryotic CYP51s. Residues within 4 Å of itraconazole in S. cerevisiae SDM are shown in bold. Residues within 4 A° of lanosterol in the human CYP51 D231A H314A mutant that has high substrate occupancy are highlighted in green (in general, possible hydrophobic interactions). Residues with their main chain nitrogen possibly involved in a water-mediated hydrogen bond network with the hydroxyl of lanosterol (M378, M487) are highlighted in gray while the residue (I379) using its main chain carbonyl to make a direct hydrogen bond with lanosterol is highlighted in gray and in bold. Some residues were where alignments and some experimental work indicate possible roles in substrate specificity and/or as causes of innate resistance to azole drugs are highlight in light blue. Selected residues identified as relevant to innate azole resistance representative of molds are illustrated using A. fumigatus and for mucormycetes they are illustrated using R. arrhizus.

Author Contributions

K.R., M.L. and B.C.M. performed the literature search, wrote parts of the review, revised and edited the final version of the article. All authors have read and agreed to the published version of the manuscript.

Funding

K.R. is a funded PhD student by the Austrian Science Fund FWF grant P32329-B entitled ‘Intrinsic azole resistance in mucormycetes’.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Kathiravan, M.K.; Salake, A.B.; Chothe, A.S.; Dudhe, P.B.; Watode, R.P.; Mukta, M.S.; Gadhwe, S. The biology and chemistry of antifungal agents: A review. Bioorg. Med. Chem. 2012, 20, 5678–5698. [Google Scholar] [CrossRef] [PubMed]
  2. Mast, N.; Zheng, W.; Stout, C.D.; Pikuleva, I.A. Antifungal azoles: Structural insights into undesired tight binding to cholesterol-metabolizing cyp46a1. Mol. Pharmacol. 2013, 84, 86–94. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Kashyap, A.; Silakari, O. Chapter 9—Triazoles: Multidimensional 5-membered nucleus for designing multitargeting agents. In Key Heterocycle Cores for Designing Multitargeting Molecules; Silakari, O., Ed.; Elsevier: Amsterdam, The Netherlands, 2018; pp. 323–342. [Google Scholar]
  4. Fisher, M.C.; Hawkins, N.J.; Sanglard, D.; Gurr, S.J. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science 2018, 360, 739–742. [Google Scholar] [CrossRef] [Green Version]
  5. Barber, A.E.; Riedel, J.; Sae-Ong, T.; Kang, K.; Brabetz, W.; Panagiotou, G.; Deising, H.B.; Kurzai, O. Effects of agricultural fungicide use on Aspergillus fumigatus abundance, antifungal susceptibility, and population structure. BioRxiv 2020. [Google Scholar] [CrossRef]
  6. Brauer, V.S.; Rezende, C.P.; Pessoni, A.M.; De Paula, R.G.; Rangappa, K.S.; Nayaka, S.C.; Gupta, V.K.; Almeida, F. Antifungal agents in agriculture: Friends and foes of public health. Biomolecules 2019, 9, 521. [Google Scholar] [CrossRef] [Green Version]
  7. Warrilow, A.G.S.; Hull, C.M.; Rolley, N.J.; Parker, J.E.; Nes, W.D.; Smith, S.N.; Kelly, D.E.; Kelly, S.L. Clotrimazole as a potent agent for treating the oomycete fish pathogen Saprolegnia parasiticathrough inhibition of sterol 14α-demethylase (cyp51). Appl. Environ. Microbiol. 2014, 80, 6154–6166. [Google Scholar] [CrossRef] [Green Version]
  8. Baumgardner, D.J. Fungal infections from human and animal contact. J. Patient-Cent. Res. Rev. 2017, 4, 78–89. [Google Scholar]
  9. Pham, D.K.; Chu, J.; Do, N.T.; Brose, F.; Degand, G.; Delahaut, P.; De Pauw, E.; Douny, C.; Van Nguyen, K.; Vu, T.D.; et al. Monitoring antibiotic use and residue in freshwater aquaculture for domestic use in vietnam. EcoHealth 2015, 12, 480–489. [Google Scholar] [CrossRef] [Green Version]
  10. Barber, A.E.; Scheufen, S.; Walther, G.; Kurzai, O.; Schmidt, V. Low rate of azole resistance in cases of avian aspergillosis in germany. Med. Mycol. 2020, 58, 1187–1190. [Google Scholar] [CrossRef]
  11. Kano, R.; Okubo, M.; Yanai, T.; Hasegawa, A.; Kamata, H. First isolation of azole-resistant Cryptococcus neoformans from feline cryptococcosis. Mycopathologia 2015, 180, 427–433. [Google Scholar] [CrossRef]
  12. Seyedmousavi, S.; Bosco, S.M.G.; de Hoog, S.; Ebel, F.; Elad, D.; Gomes, R.R.; Jacobsen, I.D.; Jensen, H.E.; Martel, A.; Mignon, B.; et al. Fungal infections in animals: A patchwork of different situations. Med. Mycol. 2018, 56, 165–187. [Google Scholar] [CrossRef]
  13. Caldas, S.S.; Arias, J.L.O.; Rombaldi, C.; Mello, L.L.; Cerqueira, M.B.R.; Martins, A.F.; Primel, E.G. Occurrence of pesticides and PPCPS in surface and drinking water in southern brazil: Data on 4-year monitoring. J. Braz. Chem. Soc. 2019, 30, 71–80. [Google Scholar] [CrossRef]
  14. Campestre, C.; Locatelli, M.; Guglielmi, P.; De Luca, E.; Bellagamba, G.; Menta, S.; Zengin, G.; Celia, C.; Di Marzio, L.; Carradori, S. Analysis of imidazoles and triazoles in biological samples after microextraction by packed sorbent. J. Enzym. Inhib. Med. Chem. 2017, 32, 1–11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Shafiei, M.; Peyton, L.; Hashemzadeh, M.; Foroumadi, A. History of the development of antifungal azoles: A review on structures, sar, and mechanism of action. Bioorganic Chem. 2020, 104, 104240. [Google Scholar] [CrossRef] [PubMed]
  16. Warrilow, A.G.; Nishimoto, A.T.; Parker, J.E.; Price, C.L.; Flowers, S.A.; Kelly, D.E.; Rogers, P.D.; Kelly, S.L. The evolution of azole resistance in Candida albicans sterol 14α-demethylase (cyp51) through incremental amino acid substitutions. Antimicrob. Agents Chemother. 2019, 63. [Google Scholar] [CrossRef] [Green Version]
  17. Schoustra, S.; Debets, A.J.M.; Rijs, A.J.M.M.; Zhang, J.; Snelders, E.; Leendertse, P.; Melchers, W.J.G.; Rietveld, A.; Zwaan, B.; Verweij, P. Environmental hotspots for azole resistance selection of Aspergillus fumigatus, the netherlands. Emerg. Infect. Dis. J. 2019, 25, 1347. [Google Scholar] [CrossRef] [Green Version]
  18. Verweij, P.E.; Chowdhary, A.; Melchers, W.J.; Meis, J.F. Azole resistance in Aspergillus fumigatus: Can we retain the clinical use of mold-active antifungal azoles? Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2016, 62, 362–368. [Google Scholar] [CrossRef] [Green Version]
  19. Zhang, Y.; Yang, H.; Turra, D.; Zhou, S.; Ayhan, D.H.; DeIulio, G.A.; Guo, L.; Broz, K.; Wiederhold, N.; Coleman, J.J.; et al. The genome of opportunistic fungal pathogen fusarium oxysporum carries a unique set of lineage-specific chromosomes. Commun. Biol. 2020, 3, 50. [Google Scholar] [CrossRef] [Green Version]
  20. Keniya, M.V.; Sabherwal, M.; Wilson, R.K.; Woods, M.A.; Sagatova, A.A.; Tyndall, J.D.A.; Monk, B.C. Crystal structures of full-length lanosterol 14α-demethylases of prominent fungal pathogens Candida albicans and Candida glabrata provide tools for antifungal discovery. Antimicrob. Agents Chemother. 2018, 62, e01134-18. [Google Scholar] [CrossRef] [Green Version]
  21. Keniya, M.V.; Ruma, Y.N.; Tyndall, J.D.A.; Monk, B.C. Heterologous expression of full-length lanosterol 14α-demethylases of prominent fungal pathogens Candida albicans and Candida glabrata provides tools for antifungal discovery. Antimicrob. Agents Chemother. 2018, 62, e01131-18. [Google Scholar]
  22. Balkis, M.M.; Leidich, S.D.; Mukherjee, P.K.; Ghannoum, M.A. Mechanisms of fungal resistance: An overview. Drugs 2002, 62, 1025–1040. [Google Scholar] [CrossRef]
  23. Monk, B.C.; Sagatova, A.A.; Hosseini, P.; Ruma, Y.N.; Wilson, R.K.; Keniya, M.V. Fungal lanosterol 14α-demethylase: A target for next-generation antifungal design. Biochim. Biophys. Acta Proteins Proteom. 2020, 1868, 140206. [Google Scholar] [CrossRef] [PubMed]
  24. Lackner, M.; Tscherner, M.; Schaller, M.; Kuchler, K.; Mair, C.; Sartori, B.; Istel, F.; Arendrup, M.C.; Lass-Flörl, C. Positions and numbers of fks mutations in Candida albicans selectively influence in vitro and in vivo susceptibilities to echinocandin treatment. Antimicrob. Agents Chemother. 2014, 58, 3626–3635. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Pérez-Cantero, A.; López-Fernández, L.; Guarro, J.; Capilla, J. Azole resistance mechanisms in Aspergillus: Update and recent advances. Int. J. Antimicrob. Agents 2020, 55, 105807. [Google Scholar] [CrossRef] [PubMed]
  26. Teo, J.Q.; Lee, S.J.; Tan, A.L.; Lim, R.S.; Cai, Y.; Lim, T.P.; Kwa, A.L. Molecular mechanisms of azole resistance in Candida bloodstream isolates. Bmc Infect. Dis. 2019, 19, 63. [Google Scholar] [CrossRef] [PubMed]
  27. Magobo, R.E.; Lockhart, S.R.; Govender, N.P. Fluconazole-resistant Candida parapsilosis strains with a Y132F substitution in the ERG11 gene causing invasive infections in a neonatal unit, south africa. Mycoses 2020, 63, 471–477. [Google Scholar] [CrossRef] [PubMed]
  28. Monk, B.C.; Tomasiak, T.M.; Keniya, M.V.; Huschmann, F.U.; Tyndall, J.D.; O’Connell, J.D., 3rd; Cannon, R.D.; McDonald, J.G.; Rodriguez, A.; Finer-Moore, J.S.; et al. Architecture of a single membrane spanning cytochrome p450 suggests constraints that orient the catalytic domain relative to a bilayer. Proc. Natl. Acad. Sci. USA 2014, 111, 3865–3870. [Google Scholar] [CrossRef] [Green Version]
  29. Patel, S.B. Plant sterols and stanols: Their role in health and disease. J. Clin. Lipidol. 2008, 2, S11–S19. [Google Scholar] [CrossRef] [Green Version]
  30. Sagatova, A.A.; Keniya, M.V.; Wilson, R.K.; Monk, B.C.; Tyndall, J.D. Structural insights into binding of the antifungal drug fluconazole to Saccharomyces cerevisiae lanosterol 14α-demethylase. Antimicrob. Agents Chemother. 2015, 59, 4982–4989. [Google Scholar] [CrossRef] [Green Version]
  31. Snelders, E.; Camps, S.M.; Karawajczyk, A.; Rijs, A.J.; Zoll, J.; Verweij, P.E.; Melchers, W.J. Genotype-phenotype complexity of the TR46/Y121F/T289A cyp51A azole resistance mechanism in Aspergillus fumigatus. Fungal Genet. Biol. Fg B 2015, 82, 129–135. [Google Scholar] [CrossRef] [PubMed]
  32. Wu, C.J.; Liu, W.L.; Lai, C.C.; Chao, C.M.; Ko, W.C.; Wang, H.C.; Dai, C.T.; Hsieh, M.I.; Choi, P.C.; Yang, J.L.; et al. Multicenter study of azole-resistant Aspergillus fumigatus clinical isolates, taiwan (1). Emerg. Infect. Dis. 2020, 26, 804–806. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Lavergne, R.A.; Morio, F.; Danner-Boucher, I.; Horeau-Langlard, D.; David, V.; Hagen, F.; Meis, J.F.; Le Pape, P. One year prospective survey of azole resistance in Aspergillus fumigatus at a french cystic fibrosis reference centre: Prevalence and mechanisms of resistance. J. Antimicrob. Chemother. 2019, 74, 1884–1889. [Google Scholar] [CrossRef] [PubMed]
  34. Resendiz-Sharpe, A.; Mercier, T.; Lestrade, P.P.A.; van der Beek, M.T.; von dem Borne, P.A.; Cornelissen, J.J.; De Kort, E.; Rijnders, B.J.A.; Schauwvlieghe, A.; Verweij, P.E.; et al. Prevalence of voriconazole-resistant invasive Aspergillosis and its impact on mortality in haematology patients. J. Antimicrob. Chemother. 2019, 74, 2759–2766. [Google Scholar] [CrossRef] [PubMed]
  35. Rivero-Menendez, O.; Soto-Debran, J.C.; Medina, N.; Lucio, J.; Mellado, E.; Alastruey-Izquierdo, A. Molecular identification, antifungal susceptibility testing, and mechanisms of azole resistance in Aspergillus species received within a surveillance program on antifungal resistance in spain. Antimicrob. Agents Chemother. 2019, 63, e00865-19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Leonardelli, F.; Macedo, D.; Dudiuk, C.; Cabeza, M.S.; Gamarra, S.; Garcia-Effron, G. Aspergillus fumigatus intrinsic fluconazole resistance is due to the naturally occurring T301I substitution in cyp51ap. Antimicrob. Agents Chemother. 2016, 60, 5420–5426. [Google Scholar] [CrossRef] [Green Version]
  37. Alcazar-Fuoli, L.; Cuesta, I.; Rodriguez-Tudela, J.L.; Cuenca-Estrella, M.; Sanglard, D.; Mellado, E. Three-dimensional models of 14α-sterol demethylase (cyp51a) from Aspergillus lentulus and Aspergillus fumigatus: An insight into differences in voriconazole interaction. Int. J. Antimicrob. Agents 2011, 38, 426–434. [Google Scholar] [CrossRef] [Green Version]
  38. Park, S.; Perlin, D.S. Establishing surrogate markers for fluconazole resistance in Candida albicans. Microb. Drug Resist. (Larchmt. N. Y.) 2005, 11, 232–238. [Google Scholar] [CrossRef]
  39. Whaley, S.G.; Berkow, E.L.; Rybak, J.M.; Nishimoto, A.T.; Barker, K.S.; Rogers, P.D. Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species. Front. Microbiol. 2016, 7, 2173. [Google Scholar] [CrossRef] [Green Version]
  40. Accoceberry, I.; Rougeron, A.; Biteau, N.; Chevrel, P.; Fitton-Ouhabi, V.; Noël, T. A CTG Candida yeast genetically engineered for the genotype-phenotype characterization of azole antifungal resistance in human pathogenic yeasts. Antimicrob. Agents Chemother. 2017, 62, e01483-17. [Google Scholar] [CrossRef] [Green Version]
  41. Lamb, D.C.; Kelly, D.E.; Schunck, W.H.; Shyadehi, A.Z.; Akhtar, M.; Lowe, D.J.; Baldwin, B.C.; Kelly, S.L. The mutation T315A in Candida albicans sterol 14alpha-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. J. Biol. Chem. 1997, 272, 5682–5688. [Google Scholar] [CrossRef] [Green Version]
  42. Muñoz, J.F.; Gade, L.; Chow, N.A.; Loparev, V.N.; Juieng, P.; Berkow, E.L.; Farrer, R.A.; Litvintseva, A.P.; Cuomo, C.A. Genomic insights into multidrug-resistance, mating and virulence in Candida auris and related emerging species. Nat. Commun. 2018, 9, 5346. [Google Scholar] [CrossRef] [Green Version]
  43. Healey, K.R.; Kordalewska, M.; Jiménez Ortigosa, C.; Singh, A.; Berrío, I.; Chowdhary, A.; Perlin, D.S. Limited ERG11 mutations identified in isolates of Candida auris directly contribute to reduced azole susceptibility. Antimicrob. Agents Chemother. 2018, 62. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Sionov, E.; Chang, Y.C.; Garraffo, H.M.; Dolan, M.A.; Ghannoum, M.A.; Kwon-Chung, K.J. Identification of a Cryptococcus neoformans cytochrome p450 lanosterol 14α-demethylase (ERG11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole. Antimicrob. Agents Chemother. 2012, 56, 1162–1169. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Xiang, M.J.; Liu, J.Y.; Ni, P.H.; Wang, S.; Shi, C.; Wei, B.; Ni, Y.X.; Ge, H.L. Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans. Fems Yeast Res. 2013, 13, 386–393. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Martini, C.; Torelli, R.; de Groot, T.; De Carolis, E.; Morandotti, G.A.; De Angelis, G.; Posteraro, B.; Meis, J.F.; Sanguinetti, M. Prevalence and clonal distribution of azole-resistant Candida parapsilosis isolates causing bloodstream infections in a large italian hospital. Front. Cell. Infect. Microbiol. 2020, 10, 232. [Google Scholar] [CrossRef] [PubMed]
  47. Bosco-Borgeat, M.E.; Mazza, M.; Taverna, C.G.; Córdoba, S.; Murisengo, O.A.; Vivot, W.; Davel, G. Amino acid substitution in Cryptococcus neoformans lanosterol 14-α-demethylase involved in fluconazole resistance in clinical isolates. Rev. Argent. Microbiol. 2016, 48, 137–142. [Google Scholar] [CrossRef] [Green Version]
  48. Couzigou, C.; Gabriel, F.; Biteau, N.; Fitton-Ouhabi, V.; Noël, T.; Accoceberry, I. Two missense mutations, E123Q and K151E, identified in the ERG11 allele of an azole-resistant isolate of Candida kefyr recovered from a stem cell transplant patient for acute myeloid leukemia. Med. Mycol. Case Rep. 2014, 5, 12–15. [Google Scholar] [CrossRef]
  49. Caramalho, R.; Tyndall, J.D.A.; Monk, B.C.; Larentis, T.; Lass-Flörl, C.; Lackner, M. Intrinsic short-tailed azole resistance in mucormycetes is due to an evolutionary conserved aminoacid substitution of the lanosterol 14α-demethylase. Sci. Rep. 2017, 7, 15898. [Google Scholar] [CrossRef]
  50. Bernhardt, A.; Meyer, W.; Rickerts, V.; Aebischer, T.; Tintelnot, K. Identification of 14-α-lanosterol demethylase (cyp51) in Scedosporium species. Antimicrob. Agents Chemother. 2018, 62, e02599-17. [Google Scholar] [CrossRef] [Green Version]
  51. Zulak, K.G.; Cox, B.A.; Tucker, M.A.; Oliver, R.P.; Lopez-Ruiz, F.J. Improved detection and monitoring of fungicide resistance in Blumeria graminis f. sp. hordei with high-throughput genotype quantification by digital PCR. Front. Microbiol. 2018, 9, 706. [Google Scholar] [CrossRef]
  52. Mullins, J.G.; Parker, J.E.; Cools, H.J.; Togawa, R.C.; Lucas, J.A.; Fraaije, B.A.; Kelly, D.E.; Kelly, S.L. Molecular modelling of the emergence of azole resistance in Mycosphaerella graminicola. PLoS ONE 2011, 6, e20973. [Google Scholar] [CrossRef]
  53. Heick, T.M.; Justesen, A.F.; Jørgensen, L.N. Resistance of wheat pathogen zymoseptoria tritici to DMI and QOI fungicides in the nordic-baltic region—A status. Eur. J. Plant Pathol. 2017, 149, 669–682. [Google Scholar] [CrossRef]
  54. Pereira, D.A.; McDonald, B.A.; Brunner, P.C. Mutations in the cyp51 gene reduce DMI sensitivity in Parastagonospora nodorum populations in europe and china. Pest Manag. Sci. 2017, 73, 1503–1510. [Google Scholar] [CrossRef] [PubMed]
  55. Pandey, B.; Sharma, P. Structural insights into impact of y134f mutation and discovery of novel fungicidal compounds against cyp51 in puccinia triticina. J. Cell. Biochem. 2018, 119, 2588–2603. [Google Scholar] [CrossRef]
  56. Frenkel, O.; Cadle-Davidson, L.; Wilcox, W.F.; Milgroom, M.G. Mechanisms of resistance to an azole fungicide in the grapevine powdery mildew fungus, Erysiphe necator. Phytopathology 2015, 105, 370–377. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Monk, B.C.; Keniya, M.V.; Sabherwal, M.; Wilson, R.K.; Graham, D.O.; Hassan, H.F.; Chen, D.; Tyndall, J.D.A. Azole resistance reduces susceptibility to the tetrazole antifungal VT-1161. Antimicrob. Agents Chemother. 2019, 63, e02114-18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  58. Sagatova, A.A.; Keniya, M.V.; Tyndall, J.D.A.; Monk, B.C. Impact of homologous resistance mutations from pathogenic yeast on Saccharomyces cerevisiae lanosterol 14α-demethylase. Antimicrob. Agents Chemother. 2018, 62, e02242-17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  59. Sagatova, A.A.; Keniya, M.V.; Wilson, R.K.; Sabherwal, M.; Tyndall, J.D.; Monk, B.C. Triazole resistance mediated by mutations of a conserved active site tyrosine in fungal lanosterol 14α-demethylase. Sci. Rep. 2016, 6, 26213. [Google Scholar] [CrossRef] [Green Version]
  60. Lockhart, S.R. Candida auris and multidrug resistance: Defining the new normal. Fungal Genet. Biol. Fg B 2019, 131, 103243. [Google Scholar] [CrossRef]
  61. Mann, P.A.; Parmegiani, R.M.; Wei, S.Q.; Mendrick, C.A.; Li, X.; Loebenberg, D.; DiDomenico, B.; Hare, R.S.; Walker, S.S.; McNicholas, P.M. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome p450 14alpha-demethylase. Antimicrob. Agents Chemother. 2003, 47, 577–581. [Google Scholar] [CrossRef] [Green Version]
  62. Tashiro, M.; Izumikawa, K.; Hirano, K.; Ide, S.; Mihara, T.; Hosogaya, N.; Takazono, T.; Morinaga, Y.; Nakamura, S.; Kurihara, S.; et al. Correlation between triazole treatment history and susceptibility in clinically isolated Aspergillus fumigatus. Antimicrob. Agents Chemother. 2012, 56, 4870–4875. [Google Scholar] [CrossRef] [Green Version]
  63. Alcazar-Fuoli, L.; Mellado, E.; Cuenca-Estrella, M.; Sanglard, D. Probing the role of point mutations in the cyp51a gene from Aspergillus fumigatus in the model yeast Saccharomyces cerevisiae. Med. Mycol. 2011, 49, 276–284. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Prigitano, A.; Esposto, M.C.; Romanò, L.; Auxilia, F.; Tortorano, A.M. Azole-resistant Aspergillus fumigatus in the italian environment. J. Glob. Antimicrob. Resist. 2019, 16, 220–224. [Google Scholar] [CrossRef] [PubMed]
  65. Meis, J.F.; Chowdhary, A.; Rhodes, J.L.; Fisher, M.C.; Verweij, P.E. Clinical implications of globally emerging azole resistance in Aspergillus fumigatus. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 2016, 371, 20150460. [Google Scholar] [CrossRef] [Green Version]
  66. Assress, H.A.; Nyoni, H.; Mamba, B.B.; Msagati, T.A.M. Occurrence and risk assessment of azole antifungal drugs in water and wastewater. Ecotoxicol. Environ. Saf. 2020, 187, 109868. [Google Scholar] [CrossRef] [PubMed]
  67. Tyndall, J.D.; Sabherwal, M.; Sagatova, A.A.; Keniya, M.V.; Negroni, J.; Wilson, R.K.; Woods, M.A.; Tietjen, K.; Monk, B.C. Structural and functional elucidation of yeast lanosterol 14α-demethylase in complex with agrochemical antifungals. PLoS ONE 2016, 11, e0167485. [Google Scholar] [CrossRef]
  68. Ullmann, A.J.; Aguado, J.M.; Arikan-Akdagli, S.; Denning, D.W.; Groll, A.H.; Lagrou, K.; Lass-Flörl, C.; Lewis, R.E.; Munoz, P.; Verweij, P.E.; et al. Diagnosis and management of aspergillus diseases: Executive summary of the 2017 escmid-ecmm-ers guideline. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 2018, 24 (Suppl. 1), e1–e38. [Google Scholar] [CrossRef] [Green Version]
  69. Wiederhold, N.P.; Patterson, T.F. Emergence of azole resistance in Aspergillus. Semin. Respir. Crit. Care Med. 2015, 36, 673–680. [Google Scholar] [CrossRef]
  70. Wiederhold, N.P. Antifungal resistance: Current trends and future strategies to combat. Infect. Drug Resist. 2017, 10, 249–259. [Google Scholar] [CrossRef] [Green Version]
  71. Geneme Grima, M.A.; Zemene, M.; Mamuye, Y.; Getaneh, G. A review on aspergillosis in poultry. J. Vet. Sci. Technol. 2016, 7, 382. [Google Scholar]
  72. Ainsworth, G.C.; Rewell, R.E. The incidence of aspergillosis in captive wild birds. J. Comp. Pathol. Ther. 1949, 59, 213–IN217. [Google Scholar] [CrossRef]
  73. Beernaert, L.A.; Pasmans, F.; Van Waeyenberghe, L.; Haesebrouck, F.; Martel, A. Aspergillus infections in birds: A review. Avian Pathol. 2010, 39, 325–331. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Department of Conservation. Available online: https://www.doc.govt.nz/our-work/kakapo-recovery/what-we-do/kakapo-aspergillosis-outbreak/ (accessed on 30 November 2020).
  75. Kermani, F.; Shams-Ghahfarokhi, M.; Gholami-Shabani, M.; Razzaghi-Abyaneh, M. Diversity, molecular phylogeny and fingerprint profiles of airborne Aspergillus species using random amplified polymorphic DNA. World J. Microbiol. Biotechnol. 2016, 32, 96. [Google Scholar] [CrossRef] [PubMed]
  76. Godeau, C.; Reboux, G.; Scherer, E.; Laboissiere, A.; Lechenault-Bergerot, C.; Millon, L.; Rocchi, S. Azole-resistant Aspergillus fumigatus in the hospital: Surveillance from flower beds to corridors. Am. J. Infect. Control 2020, 48, 702–704. [Google Scholar] [CrossRef] [PubMed]
  77. Hagiwara, D. Isolation of azole-resistant Aspergillus fumigatus from imported plant bulbs in japan and the effect of fungicide treatment. J. Pestic. Sci. 2020, 45, 147–150. [Google Scholar] [CrossRef]
  78. Nakano, Y.; Tashiro, M.; Urano, R.; Kikuchi, M.; Ito, N.; Moriya, E.; Shirahige, T.; Mishima, M.; Takazono, T.; Miyazaki, T.; et al. Characteristics of azole-resistant Aspergillus fumigatus attached to agricultural products imported to japan. J. Infect. Chemother. Off. J. Jpn. Soc. Chemother. 2020, 26, 1021–1025. [Google Scholar] [CrossRef]
  79. Buil, J.B.; Zoll, J.; Verweij, P.E.; Melchers, W.J.G. Molecular detection of azole-resistant Aspergillus fumigatus in clinical samples. Front. Microbiol. 2018, 9, 515. [Google Scholar] [CrossRef] [Green Version]
  80. Zhang, J.; Snelders, E.; Zwaan, B.J.; Schoustra, S.E.; Meis, J.F.; van Dijk, K.; Hagen, F.; van der Beek, M.T.; Kampinga, G.A.; Zoll, J.; et al. A novel environmental azole resistance mutation in Aspergillus fumigatus and a possible role of sexual reproduction in its emergence. mBio 2017, 8. [Google Scholar] [CrossRef] [Green Version]
  81. Jeanvoine, A.; Rocchi, S.; Bellanger, A.P.; Reboux, G.; Millon, L. Azole-resistant Aspergillus fumigatus: A global phenomenon originating in the environment? Med. Mal. Infect. 2020, 50, 389–395. [Google Scholar] [CrossRef]
  82. Dos Santos, R.A.C.; Rivero-Menendez, O.; Steenwyk, J.L.; Mead, M.E.; Goldman, G.H.; Alastruey-Izquierdo, A.; Rokas, A. Draft genome sequences of four Aspergillus section fumigati clinical strains. Microbiol. Resour. Announc. 2020, 9, e00856-20. [Google Scholar] [CrossRef]
  83. Samson, R.A.; Hong, S.; Peterson, S.W.; Frisvad, J.C.; Varga, J. Polyphasic taxonomy of Aspergillus section fumigati and its teleomorph Neosartorya. Stud. Mycol. 2007, 59, 147–203. [Google Scholar] [CrossRef]
  84. Mellado, E.; Alcazar-Fuoli, L.; Cuenca-Estrella, M.; Rodriguez-Tudela, J.L. Role of Aspergillus lentulus 14-α sterol demethylase (cyp51a) in azole drug susceptibility. Antimicrob. Agents Chemother. 2011, 55, 5459–5468. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  85. Alcazar-Fuoli, L.; Mellado, E.; Alastruey-Izquierdo, A.; Cuenca-Estrella, M.; Rodriguez-Tudela, J.L. Aspergillus section fumigati: Antifungal susceptibility patterns and sequence-based identification. Antimicrob. Agents Chemother. 2008, 52, 1244–1251. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  86. Chong, G.M.; Vonk, A.G.; Meis, J.F.; Dingemans, G.J.; Houbraken, J.; Hagen, F.; Gaajetaan, G.R.; van Tegelen, D.W.; Simons, G.F.; Rijnders, B.J. Interspecies discrimination of A fumigatus and siblings A. lentulus and A. felis of the Aspergillus section fumigati using the aspergenius (®) assay. Diagn. Microbiol. Infect. Dis. 2017, 87, 247–252. [Google Scholar] [CrossRef] [PubMed]
  87. Bassetti, M.; Vena, A.; Bouza, E.; Peghin, M.; Muñoz, P.; Righi, E.; Pea, F.; Lackner, M.; Lass-Flörl, C. Antifungal susceptibility testing in candida, aspergillus and cryptococcus infections: Are the mics useful for clinicians? Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 2020, 26, 1024–1033. [Google Scholar] [CrossRef]
  88. Schelenz, S.; Hagen, F.; Rhodes, J.L.; Abdolrasouli, A.; Chowdhary, A.; Hall, A.; Ryan, L.; Shackleton, J.; Trimlett, R.; Meis, J.F.; et al. First hospital outbreak of the globally emerging Candida auris in a european hospital. Antimicrob. Resist. Infect. Control 2016, 5, 35. [Google Scholar] [CrossRef] [Green Version]
  89. CDC. CDC. Available online: https://www.cdc.gov/fungal/candida-auris/index.html (accessed on 30 November 2020).
  90. Pappas, P.G.; Kauffman, C.A.; Andes, D.R.; Clancy, C.J.; Marr, K.A.; Ostrosky-Zeichner, L.; Reboli, A.C.; Schuster, M.G.; Vazquez, J.A.; Walsh, T.J.; et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2016, 62, e1–e50. [Google Scholar] [CrossRef]
  91. Arastehfar, A.; Daneshnia, F.; Hilmioğlu-Polat, S.; Fang, W.; Yaşar, M.; Polat, F.; Metin, D.Y.; Rigole, P.; Coenye, T.; Ilkit, M.; et al. First report of candidemia clonal outbreak caused by emerging fluconazole-resistant Candida parapsilosis isolates harboring Y132F and/or Y132F+K143R in turkey. Antimicrob. Agents Chemother. 2020, 64, e01001-20. [Google Scholar] [CrossRef]
  92. Kuhn, D.M.; Mikherjee, P.K.; Clark, T.A.; Pujol, C.; Chandra, J.; Hajjeh, R.A.; Warnock, D.W.; Soil, D.R.; Ghannoum, M.A. Candida parapsilosis characterization in an outbreak setting. Emerg. Infect. Dis. 2004, 10, 1074–1081. [Google Scholar] [CrossRef]
  93. Chow, N.A.; Gade, L.; Tsay, S.V.; Forsberg, K.; Greenko, J.A.; Southwick, K.L.; Barrett, P.M.; Kerins, J.L.; Lockhart, S.R.; Chiller, T.M.; et al. Multiple introductions and subsequent transmission of multidrug-resistant Candida auris in the USA: A molecular epidemiological survey. Lancet Infect. Dis. 2018, 18, 1377–1384. [Google Scholar] [CrossRef]
  94. Chaabane, F.; Graf, A.; Jequier, L.; Coste, A.T. Review on antifungal resistance mechanisms in the emerging pathogen Candida auris. Front. Microbiol. 2019, 10, 2788. [Google Scholar] [CrossRef]
  95. Lockhart, S.R.; Etienne, K.A.; Vallabhaneni, S.; Farooqi, J.; Chowdhary, A.; Govender, N.P.; Colombo, A.L.; Calvo, B.; Cuomo, C.A.; Desjardins, C.A.; et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2017, 64, 134–140. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  96. Ahmad, S.; Khan, Z.; Al-Sweih, N.; Alfouzan, W.; Joseph, L. Candida auris in various hospitals across kuwait and their susceptibility and molecular basis of resistance to antifungal drugs. Mycoses 2020, 63, 104–112. [Google Scholar] [CrossRef] [PubMed]
  97. Chow, N.A.; Muñoz, J.F.; Gade, L.; Berkow, E.L.; Li, X.; Welsh, R.M.; Forsberg, K.; Lockhart, S.R.; Adam, R.; Alanio, A.; et al. Tracing the evolutionary history and global expansion of Candida auris using population genomic analyses. mBio 2020, 11. [Google Scholar] [CrossRef] [PubMed]
  98. Köhler, J.R.; Hube, B.; Puccia, R.; Casadevall, A.; Perfect, J.R. Fungi that infect humans. Microbiol. Spectr. 2017, 5. [Google Scholar] [CrossRef]
  99. Saag, M.S.; Graybill, R.J.; Larsen, R.A.; Pappas, P.G.; Perfect, J.R.; Powderly, W.G.; Sobel, J.D.; Dismukes, W.E. Practice guidelines for the management of cryptococcal disease. Infectious diseases society of America. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2000, 30, 710–718. [Google Scholar] [CrossRef]
  100. Firacative, C.; Torres, G.; Meyer, W.; Escandón, P. Clonal dispersal of Cryptococcus gattii VGII in an endemic region of cryptococcosis in Colombia. J. Fungi (Basel, Switz.) 2019, 5, 32. [Google Scholar] [CrossRef] [Green Version]
  101. Carriconde, F.; Gilgado, F.; Arthur, I.; Ellis, D.; Malik, R.; van de Wiele, N.; Robert, V.; Currie, B.J.; Meyer, W. Clonality and α-a recombination in the australian Cryptococcus gattii VGII population--an emerging outbreak in Australia. PLoS ONE 2011, 6, e16936. [Google Scholar] [CrossRef] [Green Version]
  102. Duncan, C.; Schwantje, H.; Stephen, C.; Campbell, J.; Bartlett, K. Cryptococcus gattii in wildlife of Vancouver island, British Columbia, Canada. J. Wildl. Dis. 2006, 42, 175–178. [Google Scholar] [CrossRef] [Green Version]
  103. Sionov, E.; Chang, Y.C.; Kwon-Chung, K.J. Azole heteroresistance in Cryptococcus neoformans: Emergence of resistant clones with chromosomal disomy in the mouse brain during fluconazole treatment. Antimicrob. Agents Chemother. 2013, 57, 5127–5130. [Google Scholar] [CrossRef] [Green Version]
  104. Chen, Y.C.; Chang, T.Y.; Liu, J.W.; Chen, F.J.; Chien, C.C.; Lee, C.H.; Lu, C.H. Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: A 12-year longitudinal study. Bmc Infect. Dis. 2015, 15, 277. [Google Scholar] [CrossRef] [Green Version]
  105. Mpoza, E.; Rhein, J.; Abassi, M. Emerging fluconazole resistance: Implications for the management of cryptococcal meningitis. Med. Mycol. Case Rep. 2018, 19, 30–32. [Google Scholar] [CrossRef]
  106. Ventoulis, I.; Sarmourli, T.; Amoiridou, P.; Mantzana, P.; Exindari, M.; Gioula, G.; Vyzantiadis, T.A. Bloodstream infection by Saccharomyces cerevisiae in two covid-19 patients after receiving supplementation of Saccharomyces in the ICU. J. Fungi (Basel, Switzerland) 2020, 6, 98. [Google Scholar] [CrossRef]
  107. Parapouli, M.; Vasileiadis, A.; Afendra, A.S.; Hatziloukas, E. Saccharomyces cerevisiae and its industrial applications. Aims Microbiol. 2020, 6, 1–31. [Google Scholar] [CrossRef]
  108. Lin, C.Y.; Alexander, C.; Steelman, A.J.; Warzecha, C.M.; de Godoy, M.R.C.; Swanson, K.S. Effects of a Saccharomyces cerevisiae fermentation product on fecal characteristics, nutrient digestibility, fecal fermentative end-products, fecal microbial populations, immune function, and diet palatability in adult dogs1. J. Anim. Sci. 2019, 97, 1586–1599. [Google Scholar] [CrossRef] [PubMed]
  109. van der Hoek, S.A.; Darbani, B.; Zugaj, K.E.; Prabhala, B.K.; Biron, M.B.; Randelovic, M.; Medina, J.B.; Kell, D.B.; Borodina, I. Engineering the yeast Saccharomyces cerevisiae for the production of l-(+)-ergothioneine. Front. Bioeng. Biotechnol. 2019, 7, 262. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  110. Baeshen, N.A.; Baeshen, M.N.; Sheikh, A.; Bora, R.S.; Ahmed, M.M.; Ramadan, H.A.; Saini, K.S.; Redwan, E.M. Cell factories for insulin production. Microb. Cell Factories 2014, 13, 141. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  111. Karathia, H.; Vilaprinyo, E.; Sorribas, A.; Alves, R. Saccharomyces cerevisiae as a model organism: A comparative study. PLoS ONE 2011, 6, e16015. [Google Scholar] [CrossRef] [Green Version]
  112. Cornely, O.A.; Alastruey-Izquierdo, A.; Arenz, D.; Chen, S.C.A.; Dannaoui, E.; Hochhegger, B.; Hoenigl, M.; Jensen, H.E.; Lagrou, K.; Lewis, R.E.; et al. Global guideline for the diagnosis and management of mucormycosis: An initiative of the european confederation of medical mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect. Dis. 2019, 19, e405–e421. [Google Scholar] [CrossRef]
  113. Lackner, M.; de Hoog, G.S.; Verweij, P.E.; Najafzadeh, M.J.; Curfs-Breuker, I.; Klaassen, C.H.; Meis, J.F. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob. Agents Chemother. 2012, 56, 2635–2642. [Google Scholar] [CrossRef] [Green Version]
  114. Spec, A.; Connolly, P.; Montejano, R.; Wheat, L.J. In vitro activity of isavuconazole against fluconazole-resistant isolates of Histoplasma capsulatum. Med. Mycol. 2018, 56, 834–837. [Google Scholar] [CrossRef] [Green Version]
  115. Wheat, L.J.; Connolly, P.; Smedema, M.; Rogers, P.D. Antifungal drug resistance in histoplasmosis. In Antimicrobial Drug Resistance: Clinical and Epidemiological Aspects; Mayers, D.L., Ed.; Humana Press: Totowa, NJ, USA, 2009; pp. 987–992. [Google Scholar]
  116. Walther, G.; Wagner, L.; Kurzai, O. Updates on the taxonomy of mucorales with an emphasis on clinically important taxa. J. Fungi (Basel, Switz.) 2019, 5, 106. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  117. Takahashi, J.P.F.; Feliciano, L.M.; Santos, D.C.S.; Ramos, S.; Oliveira, R.A.; Attili-Angelis, D.; Rodrigues, N.R.; Sampaio, J.L.M.; dos Anjos Martins, M.; Melhem, M.S.C. Could fungicides lead to azole drug resistance in a cross-resistance manner among environmental Cryptococcus strains? Curr. Fungal Infect. Rep. 2020, 14, 9–14. [Google Scholar] [CrossRef]
  118. Kleinkauf, N.; Verweij, P.E.; Arendrup, M.C.; Donnelly, P.J.; Cuenca-Estrella, M.; Fraaije, B.; Melchers, W.J.G.; Adriaenssens, N.; Kema, G.H.J.; Ullmann, A.; et al. Risk Assessment on the Impact of Environmental Usage of Triazoles on the Development and Spread of Resistance to Medical Triazoles in Aspergillus Species; ECDC: Stockholm, Sweden, 2013. [Google Scholar]
  119. Tucker, M.A.; Lopez-Ruiz, F.; Cools, H.J.; Mullins, J.G.; Jayasena, K.; Oliver, R.P. Analysis of mutations in west australian populations of Blumeria graminis f. sp. hordei cyp51 conferring resistance to DMI fungicides. Pest Manag. Sci. 2020, 76, 1265–1272. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  120. Draz, I.S.; Abou-Elseoud, M.S.; Kamara, A.-E.M.; Alaa-Eldein, O.A.-E.; El-Bebany, A.F. Screening of wheat genotypes for leaf rust resistance along with grain yield. Ann. Agric. Sci. 2015, 60, 29–39. [Google Scholar] [CrossRef] [Green Version]
  121. Stammler, G.; Cordero, J.; Koch, A.; Semar, M.; Schlehuber, S. Role of the Y134F mutation in cyp51 and overexpression of cyp51 in the sensitivity response of Puccinia triticina to epoxiconazole. Crop Prot. 2009, 28, 891–897. [Google Scholar] [CrossRef]
  122. Couch, R.B.; Webster, R.G.; Kasel, J.A.; Cate, T.R. Efficacy of purified influenza subunit vaccines and relation to the major antigenic determinants on the hemagglutinin molecule. J. Infect. Dis. 1979, 140, 553–559. [Google Scholar] [CrossRef] [PubMed]
  123. Savocchia, S.; Stummer, B.E.; Wicks, T.J.; van Heeswijck, R.; Scott, E.S. Reduced sensitivity of Uncinula necator to sterol demethylation inhibiting fungicides in southern australian vineyards. Australas. Plant Pathol. 2004, 33, 465–473. [Google Scholar] [CrossRef]
  124. Xisto, M.I.; Caramalho, R.D.; Rocha, D.A.; Ferreira-Pereira, A.; Sartori, B.; Barreto-Bergter, E.; Junqueira, M.L.; Lass-Flörl, C.; Lackner, M. Pan-azole-resistant Candida tropicalis carrying homozygous ERG11 mutations at position k143r: A new emerging superbug? J. Antimicrob. Chemother. 2017, 72, 988–992. [Google Scholar]
  125. Sabino, R.; Veríssimo, C.; Pereira, Á.A.; Antunes, F. Candida auris, an agent of hospital-associated outbreaks: Which challenging issues do we need to have in mind? Microorganisms 2020, 8, 181. [Google Scholar] [CrossRef] [Green Version]
  126. Kordalewska, M.; Lee, A.; Zhao, Y.; Perlin, D.S. Detection of Candida auris antifungal drug resistance markers directly from clinical skin swabs. Antimicrob. Agents Chemother. 2019, 63. [Google Scholar] [CrossRef]
  127. Eyre, D.W.; Sheppard, A.E.; Madder, H.; Moir, I.; Moroney, R.; Quan, T.P.; Griffiths, D.; George, S.; Butcher, L.; Morgan, M.; et al. A Candida auris outbreak and its control in an intensive care setting. N. Engl. J. Med. 2018, 379, 1322–1331. [Google Scholar] [CrossRef] [PubMed]
  128. Ruiz-Gaitán, A.; Martínez, H.; Moret, A.M.; Calabuig, E.; Tasias, M.; Alastruey-Izquierdo, A.; Zaragoza, Ó.; Mollar, J.; Frasquet, J.; Salavert-Lletí, M.; et al. Detection and treatment of Candida auris in an outbreak situation: Risk factors for developing colonization and candidemia by this new species in critically ill patients. Expert Rev. Anti-Infect. Ther. 2019, 17, 295–305. [Google Scholar]
  129. Forastiero, A.; Mesa-Arango, A.C.; Alastruey-Izquierdo, A.; Alcazar-Fuoli, L.; Bernal-Martinez, L.; Pelaez, T.; Lopez, J.F.; Grimalt, J.O.; Gomez-Lopez, A.; Cuesta, I.; et al. Candida tropicalis antifungal cross-resistance is related to different azole target (erg11p) modifications. Antimicrob. Agents Chemother. 2013, 57, 4769–4781. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  130. Flowers, S.A.; Colón, B.; Whaley, S.G.; Schuler, M.A.; Rogers, P.D. Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans. Antimicrob. Agents Chemother. 2015, 59, 450–460. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  131. Cools, H.J.; Fraaije, B.A. Update on mechanisms of azole resistance in Mycosphaerella graminicola and implications for future control. Pest Manag. Sci. 2013, 69, 150–155. [Google Scholar] [CrossRef]
  132. Perlin, D.S.; Rautemaa-Richardson, R.; Alastruey-Izquierdo, A. The global problem of antifungal resistance: Prevalence, mechanisms, and management. Lancet Infect. Dis. 2017, 17, e383–e392. [Google Scholar] [CrossRef]
  133. Chen, Y.; Lu, Z.; Zhao, J.; Zou, Z.; Gong, Y.; Qu, F.; Bao, Z.; Qiu, G.; Song, M.; Zhang, Q.; et al. Epidemiology and molecular characterizations of azole resistance in clinical and environmental Aspergillus fumigatus isolates from China. Antimicrob. Agents Chemother. 2016, 60, 5878–5884. [Google Scholar] [CrossRef] [Green Version]
  134. Chowdhary, A.; Sharma, C.; van den Boom, M.; Yntema, J.B.; Hagen, F.; Verweij, P.E.; Meis, J.F. Multi-azole-resistant Aspergillus fumigatus in the environment in Tanzania. J. Antimicrob. Chemother. 2014, 69, 2979–2983. [Google Scholar] [CrossRef]
  135. Bromley, M.J.; van Muijlwijk, G.; Fraczek, M.G.; Robson, G.; Verweij, P.E.; Denning, D.W.; Bowyer, P. Occurrence of azole-resistant species of Aspergillus in the UK environment. J. Glob. Antimicrob. Resist. 2014, 2, 276–279. [Google Scholar] [CrossRef]
  136. Cao, D.; Wu, R.; Dong, S.; Wang, F.; Ju, C.; Yu, S.; Xu, S.; Fang, H.; Yu, Y. Five-year survey (2014 to 2018) of azole resistance in environmental Aspergillus fumigatus isolates from china. Antimicrob. Agents Chemother. 2020, 64. [Google Scholar] [CrossRef]
  137. Caetano, L.A.; Faria, T.; Springer, J.; Loeffler, J.; Viegas, C. Antifungal-resistant mucorales in different indoor environments. Mycology 2019, 10, 75–83. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  138. Tomlin, C. The Pesticide Manual: A World Compendium, 11th ed.; British Crop Protection Council: Farnham, Surrey, UK, 1997. [Google Scholar]
  139. Cairns, T.; Siegmund, E.G.; Chiu, K.S.; Nelson, R. Residue characterization of triadimefon in grapes by gas chromatography and mass spectrometry/mass spectrometry. Biomed. Environ. Mass Spectrom. 1989, 18, 110–115. [Google Scholar] [CrossRef] [PubMed]
  140. Hay, R. Therapy of skin, hair and nail fungal infections. J. Fungi 2018, 4, 99. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  141. Caetano, L.A.; Faria, T.; Batista, A.C.; Viegas, S.; Viegas, C. Assessment of occupational exposure to azole resistant fungi in 10 portuguese bakeries. AIMS Microbiol. 2017, 3, 960–975. [Google Scholar] [CrossRef] [Green Version]
Jof 07 00001 g001 550
Figure 1. Structural view of the ligand-binding pocket of S. cerevisiae SDM (sterol 14-alpha demethylase) with the azole inhibitor short-tailed VCZ (voriconazole) and the long-tailed ITC (itraconazole) overlaid. The triazole of each drug is the 5th ligand of the heme iron (large red ball) and C470 is the 6th ligand. AA (amino acid) residues important for azole binding and/or azole resistance discussed in this review are shown with their carbons in light green. A list of this AAs is given in Supplementary Table S3. Relevant structural features, including the heme porphyrin, are given in green. Water-mediated hydrogen bond networks important for the binding of VCZ in the active site and ITC in the substrate entry channel are shown as yellow dashes.
Figure 1. Structural view of the ligand-binding pocket of S. cerevisiae SDM (sterol 14-alpha demethylase) with the azole inhibitor short-tailed VCZ (voriconazole) and the long-tailed ITC (itraconazole) overlaid. The triazole of each drug is the 5th ligand of the heme iron (large red ball) and C470 is the 6th ligand. AA (amino acid) residues important for azole binding and/or azole resistance discussed in this review are shown with their carbons in light green. A list of this AAs is given in Supplementary Table S3. Relevant structural features, including the heme porphyrin, are given in green. Water-mediated hydrogen bond networks important for the binding of VCZ in the active site and ITC in the substrate entry channel are shown as yellow dashes.
Jof 07 00001 g001
Jof 07 00001 g002 550
Figure 2. Structural view of the ligand-binding pocket of the human CYP51 D231A H314 mutant catalytic domain (Protein Data Bank ID: 6UEZ) interacting via hydrogen bonds (yellow dashes) with the hydroxyl of lanosterol (carbons in yellow). The heme is given in blue with the iron as a large red ball. Amino acid residues involved in the hydrogen bonding directly or as part of a water-mediated network are indicated. A list of all key AA residues for the main structures of the SDM are given in Supplementary Table S3.
Figure 2. Structural view of the ligand-binding pocket of the human CYP51 D231A H314 mutant catalytic domain (Protein Data Bank ID: 6UEZ) interacting via hydrogen bonds (yellow dashes) with the hydroxyl of lanosterol (carbons in yellow). The heme is given in blue with the iron as a large red ball. Amino acid residues involved in the hydrogen bonding directly or as part of a water-mediated network are indicated. A list of all key AA residues for the main structures of the SDM are given in Supplementary Table S3.
Jof 07 00001 g002
Table
Table 1. Pathogenic fungi with naturally occurring amino acid (AA) substitutions in the active site of sterol 14α-demethylase (SDM; CYP51 enzyme of the cytochrome P450 superfamily) and correlated azole resistance.
Table 1. Pathogenic fungi with naturally occurring amino acid (AA) substitutions in the active site of sterol 14α-demethylase (SDM; CYP51 enzyme of the cytochrome P450 superfamily) and correlated azole resistance.
GenusSpeciesPhylumAA Change in Active Site2nd MutationGeneCorrelated Resistance *Ref.
animal-pathogenic fungiAjellomycescapsulatusAscomycotaY136F ERG11FLC, ITC[28]
AspergillusfumigatusAscomycotaY121F(TR46) T289Acyp51AVCZ[31,32,33,34,35]
AspergillusfumigatusAscomycotaI301 cyp51AFLC[36]
AspergilluslentulusAscomycotan.a. cyp51AVCZ[37]
CandidaalbicansAscomycotaG464S ERG11FLC[38]
CandidaalbicansAscomycotaY132F, K143R ERG11FLC, VCZ[39,40]
CandidaalbicansAscomycotaT315A ERG11FLC[41]
CandidaaurisAscomycotaY132F, K143R ERG11FLC[41]
CandidaorthopsilosisAscomycotaY132F, K143R ERG11FLC, VCZ[42]
CandidaparapsilosisAscomycotaY132FP6S, C45G, G50L, D460TERG11FLC, VCZ[43,44]
CandidaparapsilosisAscomycotaY132FR398IERG11FLC, VCZ[45,46]
CandidatropicalisAscomycotaY132F, K143R ERG11FLC, VCZ[40,43]
CryptococcusneoformansBasidiomycotaY145F ERG11VCZ[47]
KluyveromycesmarxianusAscomycotaK151 ERG11FLC, VCZ, ITC, PCZ[48]
MucorcircinelloidesMucormycotaF129A291CYP51 F5FLC, VCZ[49]
RhizopusarrhizusMucormycotaF129A291CYP51 F5FLC, VCZ[49]
RhizopusmicrosporusMucormycotaF129A291CYP51 F5FLC, VCZ[49]
ScedosporiumapiospermumAscomycotaY136F cyp51VCZ[50]
plant-pathogenic fungiBlumeriagraminisAscomycotaY136F/Y137F Cyp51TBC[51]
MycosphaerellagraminicolaAscomycotaY137F, G460 Cyp51TDM, TBC, EPC[52,53]
ParastagonosporanodorumAscomycotaY144F/H Cyp51PPC[54]
PucciniatriticinaBasidiomycotaY134F Cyp51EPC[55]
UncinulanecatorAscomycotaY136F Cyp51TBC[56]
Legend. Not available (n.a.), animal pathogenic fungi (includes fungi causing infections in animals and humans), gene (name of sterol 14α-demethylase-encoding gene carrying the AA substitution), fluconazole (FLC), itraconazole (ITC), posaconazole (PCZ), voriconazole (VCZ), tebuconazole (TBC), propiconazole (PPC), epoxiconazole (EPC), triadimenol (TDM), 46bp-tandem repeat in the promotor region of the 14α-demethylase gene (TR), quality of wild-type AA (quality of wt), position and quality of the amino acid change (AA change) amino acid (AA), phenylalanine (F), tyrosine (Y), threonine (T), isoleucine (I), arginine (R), lysine (K), cysteine (C), leucine (L), alanine (A), aspartic acid (D), histidine (H), proline (P), serine (S), Ajellomyces capsulatus (=Histoplasma capsulatum). The exact amino acid exchanges in A. lentulus are not described yet. * Resistance calling was performed according to EUCAST breakpoints (see Supplementary S2). Key AAs are given in Supplementary Table S3.
Table
Table 2. Relevant amino acids (AAs) in the ligand-binding pocket of sterol 14α-demethylase based on Saccharomyces cerevisiae lanosterol 14α-demethylase (see Figure 1 and Supplementary Table S2). An overview of mutations in structurally aligned amino acid position in other pathogenic fungi of plants and animals is given below.
Table 2. Relevant amino acids (AAs) in the ligand-binding pocket of sterol 14α-demethylase based on Saccharomyces cerevisiae lanosterol 14α-demethylase (see Figure 1 and Supplementary Table S2). An overview of mutations in structurally aligned amino acid position in other pathogenic fungi of plants and animals is given below.
SaccharomycesCerevisiaeY140T322G464K151G73V311
AjellomycescapsulatusY136F-----
AspergillusfumigatusY121FI301--G54A289
Aspergilluslentulus--G448S---
CandidaalbicansY132FT315AG464SK143R--
CandidaaurisY132F--K143R--
CandidaorthopsilosisY132F--K143R--
CandidaparapsilosisY132F-----
CandidatropicalisY132F--K143R--
CryptococcusneoformansY145F-----
Kluyveromycesmarxianus---K151--
MucorcircinelloidesF129----A291
RhizopusarrhizusF129----A291
RhizopusmicrosporusF129----A291
ScedosporiumapiospermumY136F-G464S---
BlumeriagraminisY136F-----
MycosphaerellagraminicolaY137F-G460---
ParastagonosporanodorumY144F/H-----
PucciniatriticinaY134F-----
UncinulanecatorY136F-----
Legend Phenylalanine (F), tyrosine (Y), threonine (T), isoleucine (I), arginine (R), lysine (K) phenylalanine (F), tyrosine (Y), threonine (T), isoleucine (I), arginine (R), lysine (K), alanine (A), histidine (H), serine (S), valine (V), amino acid substitution not yet described as relevant in these fungi (-), Ajellomyces capsulatus (=Histoplasma capsulatum).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Rosam, K.; Monk, B.C.; Lackner, M. Sterol 14α-Demethylase Ligand-Binding Pocket-Mediated Acquired and Intrinsic Azole Resistance in Fungal Pathogens. J. Fungi 2021, 7, 1. https://doi.org/10.3390/jof7010001

AMA Style

Rosam K, Monk BC, Lackner M. Sterol 14α-Demethylase Ligand-Binding Pocket-Mediated Acquired and Intrinsic Azole Resistance in Fungal Pathogens. Journal of Fungi. 2021; 7(1):1. https://doi.org/10.3390/jof7010001

Chicago/Turabian Style

Rosam, Katharina, Brian C. Monk, and Michaela Lackner. 2021. "Sterol 14α-Demethylase Ligand-Binding Pocket-Mediated Acquired and Intrinsic Azole Resistance in Fungal Pathogens" Journal of Fungi 7, no. 1: 1. https://doi.org/10.3390/jof7010001

APA Style

Rosam, K., Monk, B. C., & Lackner, M. (2021). Sterol 14α-Demethylase Ligand-Binding Pocket-Mediated Acquired and Intrinsic Azole Resistance in Fungal Pathogens. Journal of Fungi, 7(1), 1. https://doi.org/10.3390/jof7010001

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop